<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="biof2148" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biofactors</journal-id><journal-id journal-id-type="iso-abbrev">Biofactors</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1872-8081</journal-id><journal-id journal-id-type="publisher-id">BIOF</journal-id><journal-title-group><journal-title>Biofactors (Oxford, England)</journal-title></journal-title-group><issn pub-type="ppub">0951-6433</issn><issn pub-type="epub">1872-8081</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39653426</article-id><article-id pub-id-type="pmc">PMC11681305</article-id>
<article-id pub-id-type="doi">10.1002/biof.2148</article-id><article-id pub-id-type="publisher-id">BIOF2148</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Cannabidiol effects in stem cells: A systematic review</article-title><alt-title alt-title-type="left-running-head">Mesas et al.</alt-title></title-group><contrib-group><contrib id="biof2148-cr-0001" contrib-type="author"><name><surname>Mesas</surname><given-names>Cristina</given-names></name><xref rid="biof2148-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="biof2148-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="biof2148-cr-0002" contrib-type="author"><name><surname>Moreno</surname><given-names>Javier</given-names></name><xref rid="biof2148-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="biof2148-cr-0003" contrib-type="author"><name><surname>Doello</surname><given-names>Kevin</given-names></name><xref rid="biof2148-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="biof2148-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="biof2148-cr-0004" contrib-type="author"><name><surname>Pe&#x000f1;a</surname><given-names>Mercedes</given-names></name><xref rid="biof2148-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="biof2148-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="biof2148-cr-0005" contrib-type="author"><name><surname>L&#x000f3;pez&#x02010;Romero</surname><given-names>Juan M.</given-names></name><xref rid="biof2148-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="biof2148-cr-0006" contrib-type="author" corresp="yes"><name><surname>Prados</surname><given-names>Jose</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4303-7746</contrib-id><xref rid="biof2148-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="biof2148-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="biof2148-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>jcprados@ugr.es</email></address></contrib><contrib id="biof2148-cr-0007" contrib-type="author"><name><surname>Melguizo</surname><given-names>Consolaci&#x000f3;n</given-names></name><xref rid="biof2148-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="biof2148-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="biof2148-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM)</named-content>
<institution>University of Granada</institution>
<city>Granada</city>
<country country="ES">Spain</country>
</aff><aff id="biof2148-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Instituto de Investigaci&#x000f3;n Biosanitaria de Granada, (ibs.GRANADA)</institution>
<city>Granada</city>
<country country="ES">Spain</country>
</aff><aff id="biof2148-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Service of Medical Oncology</named-content>
<institution>Hospital Virgen de las Nieves</institution>
<city>Granada</city>
<country country="ES">Spain</country>
</aff><aff id="biof2148-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Organic Chemistry, Faculty of Sciences</named-content>
<institution>University of Malaga</institution>
<city>M&#x000e1;laga</city>
<country country="ES">Spain</country>
</aff><aff id="biof2148-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Anatomy and Embryology, Faculty of Medicine</named-content>
<institution>University of Granada</institution>
<city>Granada</city>
<country country="ES">Spain</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Jose Prados, Instituto de Investigaci&#x000f3;n Biosanitaria de Granada, (ibs.GRANADA), Granada 18012, Spain; Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18071 Granada, Spain.<break/>
Email: <email>jcprados@ugr.es</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2025</year></pub-date><volume>51</volume><issue seq="500">1</issue><issue-id pub-id-type="doi">10.1002/biof.v51.1</issue-id><elocation-id>e2148</elocation-id><history>
<date date-type="received"><day>12</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>22</day><month>11</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 International Union of Biochemistry and Molecular Biology--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">BioFactors</italic> published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:BIOF-51-0.pdf"/><abstract><title>Abstract</title><p>Stem cells play a critical role in human tissue regeneration and repair. In addition, cancer stem cells (CSCs), subpopulations of cancer cells sharing similar characteristics as normal stem cells, are responsible for tumor metastasis and resistance to chemo&#x02010; and radiotherapy and to tumor relapse. Interestingly, all stem cells have cannabinoid receptors, such as cannabidiol (CBD), that perform biological functions. The aim of this systematic review was to analyze the effect of CBD on both somatic stem cells (SSCs) and CSCs. Of the 276 articles analyzed, 38 were selected according to the inclusion and exclusion criteria. A total of 27 studied the effect of CBD on SSCs, finding that 44% focused on CBD differentiation effect and 56% on its protective activity. On the other hand, 11 articles looked at the effect of CBD on CSCs, including glioblastoma (64%), lung cancer (27%), and breast cancer (only one article). Our results showed that CBD exerted a differentiating and protective effect on SCCs. In addition, this molecule demonstrated an antiproliferative effect on some CSCs, although most of the analyses were performed in vitro. Therefore, although in vivo studies should be necessary to justify its clinical use, CBD and its receptors could be a specific target to act on both SSCs and CSCs.</p></abstract><abstract abstract-type="graphical"><p>CBD acts as a differentiator and protector of CSCs and exerts a significant antitumor effect against CSCs indicating a great potential as a new therapeutic strategy in regenerative medicine and oncology.<boxed-text position="anchor" content-type="graphic" id="biof2148-blkfxd-0001"><graphic xlink:href="BIOF-51-0-g004.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="biof2148-kwd-0001">stem cellscancer stem cells</kwd><kwd id="biof2148-kwd-0002">CBD</kwd><kwd id="biof2148-kwd-0003">in vitro</kwd><kwd id="biof2148-kwd-0004">in vivo</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Spanish Ministry of Science, Innovation and Universities</funding-source><award-id>RTC2019&#x02010;006870&#x02010;1</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="23"/><word-count count="15000"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January/February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="biof2148-cit-9001">
<string-name>
<surname>Mesas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Doello</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pe&#x000f1;a</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;pez&#x02010;Romero</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Prados</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Cannabidiol effects in stem cells: A systematic review</article-title>. <source>BioFactors</source>. <year>2025</year>;<volume>51</volume>(<issue>1</issue>):<elocation-id>e2148</elocation-id>. <pub-id pub-id-type="doi">10.1002/biof.2148</pub-id>
</mixed-citation>
</p></notes></front><body id="biof2148-body-0001"><def-list list-content="abbreviations" id="biof2148-dl-0001"><title>Abbreviations</title><def-item><term id="biof2148-li-0001">AD</term><def id="biof2148-li-0002"><p>adipogenesis</p></def></def-item><def-item><term id="biof2148-li-0003">AD&#x02010;MSC</term><def id="biof2148-li-0004"><p>adipose&#x02010;derived mesenchymal stem cells</p></def></def-item><def-item><term id="biof2148-li-0005">alloHCT</term><def id="biof2148-li-0006"><p>allogenic hematopoietic cell transplantation)</p></def></def-item><def-item><term id="biof2148-li-0007">ALS</term><def id="biof2148-li-0008"><p>amyothrophic lateral sclerosis</p></def></def-item><def-item><term id="biof2148-li-0009">AMSC</term><def id="biof2148-li-0010"><p>adipose mesenchymal stem cell</p></def></def-item><def-item><term id="biof2148-li-0011">APD</term><def id="biof2148-li-0012"><p>AP duration</p></def></def-item><def-item><term id="biof2148-li-0013">APL</term><def id="biof2148-li-0014"><p>alkaline phosphatase</p></def></def-item><def-item><term id="biof2148-li-0015">APSC</term><def id="biof2148-li-0016"><p>apical papilla stem cell</p></def></def-item><def-item><term id="biof2148-li-0017">BM&#x02010;MSC</term><def id="biof2148-li-0018"><p>bone marrow mesenchymal stem cells</p></def></def-item><def-item><term id="biof2148-li-0019">BRDU</term><def id="biof2148-li-0020"><p>bromodeoxyuridine</p></def></def-item><def-item><term id="biof2148-li-0021">CBD</term><def id="biof2148-li-0022"><p>cannabidiol</p></def></def-item><def-item><term id="biof2148-li-0023">CM</term><def id="biof2148-li-0024"><p>commercial</p></def></def-item><def-item><term id="biof2148-li-0025">CSCs</term><def id="biof2148-li-0026"><p>cancer stem cells</p></def></def-item><def-item><term id="biof2148-li-0027">DFC</term><def id="biof2148-li-0028"><p>2&#x02032;,7'dichlorofluoresceindiacetate</p></def></def-item><def-item><term id="biof2148-li-0029">DFSC</term><def id="biof2148-li-0030"><p>dental follicle stem cell</p></def></def-item><def-item><term id="biof2148-li-0031">DNPH</term><def id="biof2148-li-0032"><p>2,4&#x02010;dinitrophenylhydrazine</p></def></def-item><def-item><term id="biof2148-li-0033">DPSC</term><def id="biof2148-li-0034"><p>dental pulp stem cell</p></def></def-item><def-item><term id="biof2148-li-0035">GBM</term><def id="biof2148-li-0036"><p>glioblastoma multiforme</p></def></def-item><def-item><term id="biof2148-li-0037">GICs</term><def id="biof2148-li-0038"><p>glioma initiating cells</p></def></def-item><def-item><term id="biof2148-li-0039">GSC</term><def id="biof2148-li-0040"><p>glioblastoma stem cells</p></def></def-item><def-item><term id="biof2148-li-0041">GVHD</term><def id="biof2148-li-0042"><p>graft&#x02010;versus&#x02010;host disease</p></def></def-item><def-item><term id="biof2148-li-0043">hGMSC</term><def id="biof2148-li-0044"><p>human gingivial mesenchymal stem cell</p></def></def-item><def-item><term id="biof2148-li-0045">hiPSC&#x02010;CM</term><def id="biof2148-li-0046"><p>human induced pluripotent stem cell&#x02010;derived cardiomyocytes</p></def></def-item><def-item><term id="biof2148-li-0047">HNP</term><def id="biof2148-li-0048"><p>hybrid nanoparticles</p></def></def-item><def-item><term id="biof2148-li-0049">HO&#x02010;1</term><def id="biof2148-li-0050"><p>heme oxigenase&#x02010;1</p></def></def-item><def-item><term id="biof2148-li-0051">HPLDSC</term><def id="biof2148-li-0052"><p>human peridontal ligament stem cells</p></def></def-item><def-item><term id="biof2148-li-0053">IC<sub>50</sub>
</term><def id="biof2148-li-0054"><p>half&#x02010;maximal inhibitory concentration</p></def></def-item><def-item><term id="biof2148-li-0055">i.p</term><def id="biof2148-li-0056"><p>intraperitoneal</p></def></def-item><def-item><term id="biof2148-li-0057">KO</term><def id="biof2148-li-0058"><p>knock&#x02010;out</p></def></def-item><def-item><term id="biof2148-li-0059">LPS</term><def id="biof2148-li-0060"><p>lipopolysaccharides</p></def></def-item><def-item><term id="biof2148-li-0061">MOR</term><def id="biof2148-li-0062"><p>moringin</p></def></def-item><def-item><term id="biof2148-li-0063">MPLA</term><def id="biof2148-li-0064"><p>monophosphoryl lipid A</p></def></def-item><def-item><term id="biof2148-li-0065">NP</term><def id="biof2148-li-0066"><p>neuroprotective</p></def></def-item><def-item><term id="biof2148-li-0067">OSP</term><def id="biof2148-li-0068"><p>oxidative stress protection</p></def></def-item><def-item><term id="biof2148-li-0069">OTG</term><def id="biof2148-li-0070"><p>osteogenesis</p></def></def-item><def-item><term id="biof2148-li-0071">OTP</term><def id="biof2148-li-0072"><p>osteoprotection</p></def></def-item><def-item><term id="biof2148-li-0073">OTR</term><def id="biof2148-li-0074"><p>osteoregeneratio)</p></def></def-item><def-item><term id="biof2148-li-0075">PLGA</term><def id="biof2148-li-0076"><p>poly(lactic&#x02010;co&#x02010;glycolic acid)</p></def></def-item><def-item><term id="biof2148-li-0077">PE</term><def id="biof2148-li-0078"><p>piperazine erastine</p></def></def-item><def-item><term id="biof2148-li-0079">PN</term><def id="biof2148-li-0080"><p>proneural</p></def></def-item><def-item><term id="biof2148-li-0081">PPAR&#x02010;&#x003b3;</term><def id="biof2148-li-0082"><p>peroxisome proliferator&#x02010;activated receptor gamma</p></def></def-item><def-item><term id="biof2148-li-0083">rCNC</term><def id="biof2148-li-0084"><p>rat cortical neural cells</p></def></def-item><def-item><term id="biof2148-li-0085">RS</term><def id="biof2148-li-0086"><p>reticulum stress</p></def></def-item><def-item><term id="biof2148-li-0087">RXR&#x02010;&#x003b1;</term><def id="biof2148-li-0088"><p>retinoid X receptor alpha</p></def></def-item><def-item><term id="biof2148-li-0089">SSCs</term><def id="biof2148-li-0090"><p>somatic stem cells</p></def></def-item><def-item><term id="biof2148-li-0091">SSPC</term><def id="biof2148-li-0092"><p>skeletal stem and progenitor cell</p></def></def-item><def-item><term id="biof2148-li-0093">TBARS</term><def id="biof2148-li-0094"><p>triobarbituric acid&#x02010;reactive substances</p></def></def-item><def-item><term id="biof2148-li-0095">TGF&#x02010;&#x003b2;</term><def id="biof2148-li-0096"><p>transforming growth factor beta</p></def></def-item><def-item><term id="biof2148-li-0097">THC</term><def id="biof2148-li-0098"><p>tetrahydrocannabinol</p></def></def-item><def-item><term id="biof2148-li-0099">TMZ</term><def id="biof2148-li-0100"><p>temozolomide</p></def></def-item></def-list><sec id="biof2148-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Cannabidiol (CBD) is an organic molecule that belongs to the cannabinoid family, a group of terpenophenols that can be isolated from <italic toggle="yes">Cannabis sativa L</italic>. and are characterized by their potential in the treatment of certain diseases, especially neuropathies by an interaction with CB1 and CB2 receptors.<xref rid="biof2148-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="biof2148-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="biof2148-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> CBD has a huge advantage over other cannabinoids, such as tetrahydrocannabinol (THC), in that it does not have a high affinity for CB1 and CB2 receptors expressed on neural somatic cells, which disables the development of psychotropic effect in the patient.<xref rid="biof2148-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Even so, there are currently numerous studies that demonstrate the capacity of CBD as a drug against numerous pathologies, where its anti&#x02010;inflammatory and antioxidative effect stands out.<xref rid="biof2148-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> In addition, it has been shown to exert an antitumor effect, either by exerting cytotoxic, antiproliferative, or antimigratory activity.<xref rid="biof2148-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="biof2148-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Interestingly, CBD receptors have been described on the somatic stem cells (SSCs) and even in special stem cells present in tumor masses (CSCs). Some of the receptors that are expressed in human bone marrow mesenchymal stem cells (hBM&#x02010;MSCs)<xref rid="biof2148-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> and adipose tissue mesenchymal stem cell (AMSC) are the CBD receptors CB1 and CB2.<xref rid="biof2148-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> CSC such glioblastoma stem cell can also produce this receptors.<xref rid="biof2148-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Additionally, GPR55 and TRPV1 receptors can be activated by CBD, expressed both in SSCs<xref rid="biof2148-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and CSC like glioblastoma stem cells.<xref rid="biof2148-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="biof2148-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Lastly, nuclear receptor PPAR&#x02010;&#x003b3; is also expressed in stem cells.<xref rid="biof2148-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="biof2148-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> CBD has an antitumoral effect due to the activation of these receptors, reducing metastatic capacity and proliferation or activating apoptosis.<xref rid="biof2148-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> On the other hand, CBD receptors also control the differentiation, proliferation and self&#x02010;renewal in SSCs.<xref rid="biof2148-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>Nowadays, there is only a few studies that directly investigate the effect of CBD on CSC, but its potential resides on its ability to interact and modify signaling pathways involved in the stemness of CSC. For example, CBD reduces the Wnt/ &#x003b2;&#x02010;catenin pathway, which is closely related to the drug resistance of most of CSC, including ovarian cancer stem cells (OCSC).<xref rid="biof2148-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Cellular drug resistance can also be mitigated through increasing TRPV2 protein activity.<xref rid="biof2148-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Additionally, it reduces CD44 levels and NF&#x02010;&#x003ba;B signal pathway implied on CSC development.<xref rid="biof2148-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> CBD could also reduce the abnormal Id1 levels of CSC by modifying p38 signaling, triggering a regulation in other pathways involved in tumor development such STAT3 and TGF&#x02010;&#x003b2;.<xref rid="biof2148-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="biof2148-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Stem cells (SCs), a collection of undifferentiated cells that exhibit self&#x02010;renewal ability, clonality and potentiality to differentiate into other cell types,<xref rid="biof2148-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="biof2148-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> have been classically classified in totipotent, pluripotent, multipotent, oligopotent, and unipotent cells. Most stem cells are found in the embryo, but stem cells from the adult organism are an interesting target for tissue repair and renewal.<xref rid="biof2148-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="biof2148-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="biof2148-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> In addition, CSCs, a group of tumor&#x02010;mass cells that ensure self&#x02010;renewal, have been described in most cancers.<xref rid="biof2148-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="biof2148-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="biof2148-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> These cells are characterized by drug resistance mediated by some mechanism such as increased DNA repair capacity, reduced apoptotic capacity, phenotypic plasticity, or increased production of drug transport channels that increase their outflow.<xref rid="biof2148-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>In this context, the presence of SSCs in adult tissue and their ability to proliferate and differentiate gives them enormous clinical potential. For example, MSC can be grafted into a wound to stimulate others stem cells present in the body and increase their migration and differentiation in this area.<xref rid="biof2148-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="biof2148-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Some cardiac diseases have been treated using stem cells to develop cardiomyocytes with optimal electrochemical characteristics but without remarkable results.<xref rid="biof2148-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="biof2148-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> In addition, hematopoietic stem cell transplantation (HSC) has been applied in leukemia or anemia<xref rid="biof2148-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> and stem cell therapy has been used in neurological diseases such as Parkinson's, Huntington's, dementia, sclerosis, and among others.<xref rid="biof2148-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="biof2148-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Other applications of stem cells, such as diabetes mellitus type 1 treatment, infertility by differentiating stem cells into gametes, and spinal cord injury treatment, are being studied.<xref rid="biof2148-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="biof2148-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="biof2148-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> On the other hand, the CSCs present in a tumor mass constitute another new opportunity for cancer treatment. In fact, these cells are responsible for the high relapse rates of many cancers such as glioblastoma, lung cancer, pancreatic cancer, and among others, despite surgical, radiotherapeutic, and chemotherapeutic treatment. Thus, the use of molecules focused on modulating the CSC behavior represents a great opportunity for cancer therapy. Experimental therapies such as Rovalpituzumab&#x02010;tesirine, which is capable of destroying CSCs with delta ligand, or Disulfiram, which inhibits (aldehyde dehydrogenase) ALDH, are the basis of recent clinical trials<xref rid="biof2148-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and drugs such as Vismodegib, which blocks the Sonic Hedgehog pathway in CSCs, is a potent new therapeutic weapon against metastatic basal cell carcinoma.<xref rid="biof2148-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> The demonstrated presence of CBD receptors in both CCS and CSC opens up the possibility that this type of cell can be modulated by CBD toward both a differentiation process and a proliferation control process, which could be useful from a therapeutic point of view. In these cases, CBD does not interact directly with CB1 and CB2 receptors, but inducing an allosteric modulation of the receptor and their affinity with others compounds like endocannabinoids.<xref rid="biof2148-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</p><p>Thus, the objective of this systematic review was to discuss about the effect of CBD over SSC and against CSC and make comparisons in experimental designs and results obtained.</p></sec><sec sec-type="methods" id="biof2148-sec-0002"><label>2</label><title>METHODS</title><p>First, this systematic review has been registered in the OSF database, on February 7, 2024 (<ext-link xlink:href="https://doi.org/10.17605/OSF.IO/NB3G" ext-link-type="uri">https://doi.org/10.17605/OSF.IO/NB3G</ext-link>).</p><sec id="biof2148-sec-0003"><label>2.1</label><title>Study eligibility and data sources</title><p>The objective of this systematic review has been to analyze all the articles published to date that study the effect of CBD on stem cells, both CSC and SSC.</p><p>To do this, first a bibliographical search was carried out in four different electronic databases: PubMed, SCOPUS, Web of Science and Cochrane. To perform the search in PubMed, the following &#x0201c;MeSH&#x0201d; terms were used: &#x0201c;cannabidiol&#x0201d; and &#x0201c;stem cells&#x0201d;, with the formula obtained: (&#x0201c;cannabidiol&#x0201d; [MeSH Terms] OR &#x0201c;cannabidiol&#x0201d; [All Fields] OR &#x0201c;cannabidiolic&#x0201d; [All Fields]) AND (&#x0201c;stem cells&#x0201d; [MeSH Terms] OR (&#x0201c;stem&#x0201d; [All Fields] AND &#x0201c;cells&#x0201d; [All Fields]) OR &#x0201c;stem cells&#x0201d; [All Fields] OR (&#x0201c;stem&#x0201d; [All Fields] AND &#x0201c;cell&#x0201d; [All Fields]) OR &#x0201c;stem cell&#x0201d; [All Fields]). In the case of the other databases, this formula was adapted. Finally, an additional literature search was conducted to include additional articles of interest. Moreover, this systematic review has followed PRISMA guide to guarantee its correct execution.<xref rid="biof2148-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</p></sec><sec id="biof2148-sec-0004"><label>2.2</label><title>Inclusion criteria</title><p>Because this systematic review aims to analyze all articles that study the effect of CBD on stem cells, no restriction has been made by publication date. All articles that have carried out in vitro, in vivo or clinical trials have been included, as well as studies in vitro or in vivo carried out from patient biopsies or from established cell lines. Both studies on CSCs and CCS have been included. Articles that obtained CBD from plant extracts or from a commercial house have been included.</p><p>After reviewing the bibliography of the articles included in the systematic review, those that met the inclusion and exclusion criteria were also added to this systematic review.</p></sec><sec id="biof2148-sec-0005"><label>2.3</label><title>Exclusion criteria</title><p>The main exclusion criterion has been that no studies were specifically carried out on stem cells. Articles that studied the antitumor activity of CBD but did not carry out specific studies on CSCs were also excluded. Those articles that tested other types of cannabinoids other than CBD were excluded. However, those that compared different types of cannabinoids including CBD were included. Regarding language, articles that were written in a language other than Spanish, English, or French were also excluded.</p></sec><sec id="biof2148-sec-0006"><label>2.4</label><title>Study selection</title><p>Authors CM and JM carried out the first bibliographic search independently and agreed on the search formula for each database obtained 276 articles. Once the articles were obtained, those that were not original articles were not freely accessible, were repeated, and were excluded, obtaining a total of 56 articles. In the second step of the procedure, independently, CM and JM carried out a detailed reading of the articles, excluding those that did not meet the inclusion and exclusion criteria, obtaining a total of 38 articles, these being the ones that were finally analyzed in this systematic review (Figure&#x000a0;<xref rid="biof2148-fig-0001" ref-type="fig">1</xref>). It is noteworthy that no additional articles were included after performing the additional literature search.</p><fig position="float" fig-type="FIGURE" id="biof2148-fig-0001"><label>FIGURE 1</label><caption><p>Flow diagram illustrating the search and selection process for articles included in the systematic review.</p></caption><graphic xlink:href="BIOF-51-0-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="biof2148-sec-0007"><label>2.5</label><title>Data extraction</title><p>Following the procedure described, C.M. and J.M carried out the procedure independently. According to Cohen's Kappa statistic test,<xref rid="biof2148-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> there was good correlation between C.M. and J.M. Any disagreements were resolved through discussion until a consensus was reached. Otherwise, a third experienced author made the final decision (M.P). Finally, each article was subjected to a quality test independently by C.M. and J.M. This quality test has two parts, the first consists of general filters on cell lines and patient biopsies (score&#x02009;&#x02265;5). Articles that did not reach this score were excluded. The second phase consisted of questions on the isolation and study of CSCs and the effect of CBD on them. The articles were classified according to the score obtained: low quality (score 0&#x02013;5), medium quality (score 6&#x02013;15), and high quality (score 16&#x02013;20). No article was excluded by this quality criterion, with all included articles obtaining high quality ratings. Therefore, the 38 articles have been summarized in tables specifying the methodology and main results obtained, both in SSC (Tables&#x000a0;<xref rid="biof2148-tbl-0001" ref-type="table">1</xref> and <xref rid="biof2148-tbl-0002" ref-type="table">2</xref>) and on CSC (Table&#x000a0;<xref rid="biof2148-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="biof2148-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Effect of CBD on SSC differentiation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Aim</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ref</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stem cell isolation</th><th align="left" valign="bottom" rowspan="1" colspan="1">Methodology</th><th align="left" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">OTG</td><td align="left" valign="top" rowspan="1" colspan="1">Kamali et al.<xref rid="biof2148-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">MSCs obtained from the scaffold samples after the in vivo experiment</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Study of porosity, biodegradation and RT&#x02010;qPCR.</p>
<p>In vivo:</p>
<p>Adult male Wistar rats with undergone forearm ostectomy. CBD&#x02010;free&#x02010;G/nHAP or CBD&#x02010;PLGA&#x02010;G/nHAp scaffolds with 500&#x02009;&#x003bc;L of a CBD (1&#x02009;mg/mL) were added, except for controls.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0001"><list-item id="biof2148-li-0101"><p>&#x02191; motility and migration of mesenchymal stem cells in vitro.</p></list-item><list-item id="biof2148-li-0102"><p>&#x02191; osteoregenerative capacity of the scaffold in an in vivo model.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Li et al.<xref rid="biof2148-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">BM&#x02010;MSC obtained from the femur of male C57BL/J6 mice.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cytotoxicity study with CCK&#x02010;8. Measurement of alkaline phosphatase activity and analysis by RT&#x02010;qPCR and Western Blot of genes and proteins involved in osteogenesis and inflammation.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0002"><list-item id="biof2148-li-0103"><p>No cytotoxic effect</p></list-item><list-item id="biof2148-li-0104"><p>&#x02193; expression of TNF&#x02010;&#x003b1; and IL&#x02010;6 (2.5&#x02013;5&#x02009;&#x003bc;M CBD). &#x02193; inflammatory response and enhancing osteogenesis via the CB2/p38 MAPK signaling pathway.</p></list-item><list-item id="biof2148-li-0105"><p>&#x02191; Runx2, osteocalcin and CB2.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Petrescu et al.<xref rid="biof2148-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">APSC, DFSC and DPSC isolated from obtained from samples of human apical papilla, dental follicule and dental pulp respectively.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cell viability assay with Alamar blue, in addition to a mineralization assay with alizarin red assay and RT&#x02010;qPCR of some osteogenesis&#x02010;related genes.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0003"><list-item id="biof2148-li-0106"><p>&#x02191; cell proliferation in the DPSC and APSC cell lines.</p></list-item><list-item id="biof2148-li-0107"><p>&#x02191; expression of osteogenic proteins in APSCs and mineralization in the DFSC cell line.</p></list-item><list-item id="biof2148-li-0108"><p>&#x02191; the transcription of osteogenic genes such as osteonectin, osteopontin and osteocalcin.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Schmuhl et al.<xref rid="biof2148-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">AD&#x02010;MSC obtained from human subcutaneous adipose tissue biopsies.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cell migration assay and a wound healing assay were performed. For osteogenesis, RT&#x02010;qPCR and Western blotting were performed, an ALP activity assay and a mineralization assay by means of an o&#x02010;cresolphtalein complexome assay.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0004"><list-item id="biof2148-li-0109"><p>&#x02191; migration via p42/44 MAPK pathway</p></list-item><list-item id="biof2148-li-0110"><p>&#x02191; ALP activity and mineralization.</p></list-item><list-item id="biof2148-li-0111"><p>&#x02191; BMP&#x02010;2, BMP7, colony stimulating factor 2, msh homebox&#x02010;1, enamelin, VEGFB.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Yu et al.<xref rid="biof2148-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">DPSC obtained from human wisdom teeth and premolars.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cell proliferation assay was performed using CCK&#x02010;8. On the other hand, cell migration was studied by wound healing assay. Finally, the expression and activity of some osteogenic genes was studied by ALP activity assay, RT&#x02010;qPCR amplification and Western blot analysis.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0005"><list-item id="biof2148-li-0112"><p>&#x02191; cell proliferation at CBD concentrations between 0.1&#x02013;12.5&#x02009;&#x003bc;M.</p></list-item><list-item id="biof2148-li-0113"><p>&#x02191; Matrix mineralization after day 14.</p></list-item><list-item id="biof2148-li-0114"><p>&#x02191; migratory capacity of DPSCs at 2.5&#x02009;&#x003bc;M CBD dose.</p></list-item><list-item id="biof2148-li-0115"><p>&#x02191; CB1 and CB2 receptors in DPSC.</p></list-item><list-item id="biof2148-li-0116"><p>&#x02193; negative effect of TNF&#x02010;a on the migration, viability and differentiation of DPSCs by &#x02193; IL6 and IL1&#x003b2; at concentrations of 2.5&#x02009;&#x003bc;M.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ihejirika&#x02010;Lomedico et al.<xref rid="biof2148-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro SSPC cells obtained from human cancellous bone.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cell viability assay by PrestoBlue kit, proliferation by BrdU assay and osteogenic gene expression analysis by RT&#x02010;qPCR.</p>
<p>In vivo:</p>
<p>Male C57BL6 with a fracture in the anterolateral area of the femur. Treatments were divided into CTL, CBD pre&#x02010;fracture, CBD post&#x02010;fracture and CBD with osteoporosis induced by fluoxetine or by ovarectomy. CBD administration at a daily rate of 5&#x02009;mg/kg of animal by implanted osmotic pump.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:<list list-type="bullet" id="biof2148-list-0006"><list-item id="biof2148-li-0117"><p>&#x02191; cell viability at 1&#x02009;&#x003bc;M CBD and 2&#x02009;&#x003bc;M</p></list-item><list-item id="biof2148-li-0118"><p>&#x02191; expression of Runx2 and Osterix.</p></list-item></list>
</p>
<p>In vivo:<list list-type="bullet" id="biof2148-list-0007"><list-item id="biof2148-li-0119"><p>No differences were observed in bone stiffness and bone fracture repair.</p></list-item><list-item id="biof2148-li-0120"><p>CBD is able to prevent negative effects in a fluoxetine and ovariectomy induced osteoporosis</p></list-item><list-item id="biof2148-li-0121"><p>&#x02193; the delayed effect on bone regeneration in mice with this disease.</p></list-item></list>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NG</td><td align="left" valign="top" rowspan="1" colspan="1">Fihurka et al.<xref rid="biof2148-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">BM&#x02010;MSC obtained from YAC128 mice</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Evaluation of cell viability with trypan blue and anti&#x02010;inflammatory study by evaluation of IL&#x02010;6 expression by ELISA after cellular exposure to LPS. Gene expression study by RT&#x02010;qPCR of the <italic toggle="yes">htt</italic> gene.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0008"><list-item id="biof2148-li-0122"><p>&#x02193; inflammation by &#x02193; IL&#x02010;6 production.</p></list-item><list-item id="biof2148-li-0123"><p>&#x02191; cell viability.</p></list-item><list-item id="biof2148-li-0124"><p>&#x02193; <italic toggle="yes">htt</italic> gene in CBD treatment.</p></list-item><list-item id="biof2148-li-0125"><p>&#x02193;&#x02193; <italic toggle="yes">htt</italic> gene in HNP&#x02010;co&#x02010;(CBD&#x02009;+&#x02009;siRNA) treatment.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Razavi et al.<xref rid="biof2148-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vivo:</p>
<p>Adult male albino Wistar rats. CBD dissolved in 10% DMSO and 90% phosphate buffer, injecting 5&#x02009;&#x003bc;L of the solution into the lateral ventricle of the brain (50&#x02009;&#x003bc;g CBD / 5&#x02009;&#x003bc;L). After the experiment, the sample was excised and microinjected, and a fluorescence immunohistochemistry assay was performed.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0009"><list-item id="biof2148-li-0126"><p>&#x02191; cell proliferation in abstinence rats.</p></list-item><list-item id="biof2148-li-0127"><p>&#x02191; neuroblast by a &#x02191; neurogenesis in abstinence rats (&#x02191;DCX&#x02010;positive cells).</p></list-item><list-item id="biof2148-li-0128"><p>= proliferation and neurogenesis between CBD in abstinence rats and DMSO in normal rats.</p></list-item><list-item id="biof2148-li-0129"><p>&#x02193; neuronal degeneration and &#x02193; number of dark neurons by CBD treatment in abstinence rats.</p></list-item><list-item id="biof2148-li-0130"><p>= number of dark neurons between CBD in abstinence rats and DMSO in normal rats.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Lanza Cariccio et al.<xref rid="biof2148-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Human hPDLSC cells from periodontal ligament tissues.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Phenotypic evaluation by stem cell flow cytometry and microscopy. In addition, cytotoxicity was evaluated by MTT assay and gene expression by RT&#x02010;qPCR. In addition, an immunofluorescence assay has been performed.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0010"><list-item id="biof2148-li-0131"><p>No toxic effect of CBD&#x02009;+&#x02009;MOR solution.</p></list-item><list-item id="biof2148-li-0132"><p>Cytoskeletal remodeling on the cells.</p></list-item><list-item id="biof2148-li-0133"><p>&#x02191; GAP43 and Nestin in CBD&#x02009;+&#x02009;MOR treatment.</p></list-item><list-item id="biof2148-li-0134"><p>&#x02191; BDNF and GFAP neuronal and glial markers.</p></list-item><list-item id="biof2148-li-0135"><p>&#x02191; neuronal survival and differentiation capacity by PI3K/Akt/mTOR activation. Enhanced effect with MOR and CBD co&#x02010;treatment.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AD</td><td align="left" valign="top" rowspan="1" colspan="1">Fellous et al.<xref rid="biof2148-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">BM&#x02010;MSC cells obtained from the femur of female C57BL/6J mice.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Fibroblast formation capacity and MTT cytotoxicity assay. Study of the amount of adiponectin by ELISA. Glucose elicitation capacity assay. Western blot.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0011"><list-item id="biof2148-li-0136"><p>&#x02191; fibroblast colony formation capacity of BM&#x02010;MSC at 5&#x02009;&#x003bc;M CBD by a CB2&#x02010;activation pathway.</p></list-item><list-item id="biof2148-li-0137"><p>&#x02191; viability of BM&#x02010;MSC cells and induction of adipogenesis by increasing the adiponectin levels in combination with CBG due to a partially&#x02010;dependent PPAR&#x003b3; activation at 5&#x02009;&#x003bc;M CBD.</p></list-item><list-item id="biof2148-li-0138"><p>&#x02191; <italic toggle="yes">Fabp4</italic> gene expression (5&#x02009;&#x003bc;M CBD).</p></list-item><list-item id="biof2148-li-0139"><p>
<italic toggle="yes">Glut</italic> and <italic toggle="yes">Scd</italic> levels &#x02191; 5&#x02009;&#x003bc;M CBD and &#x02191;&#x02191; 5&#x02009;&#x003bc;M CBD&#x02009;+&#x02009;5&#x02009;&#x003bc;M CBG.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Chang et al.<xref rid="biof2148-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">hAD&#x02010;MSC (hTERT), hBM&#x02010;MSC and mBM&#x02010;MSC purchased.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Real&#x02010;time RT&#x02010;qPCR and assessment of PPAR&#x02010;Y and RXRa activity using a luciferase assay.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0012"><list-item id="biof2148-li-0140"><p>&#x02191;PPAR&#x02010;&#x003b3; activation at CBD concentrations above 100&#x02009;nM, but no effect on RXRa.</p></list-item><list-item id="biof2148-li-0141"><p>&#x02191; lipid accumulation in hMSC (dose&#x02010;dependent CBD, above 2.5&#x02009;&#x003bc;M) and mMSC (above 5&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0142"><p>&#x02191; adipogenic genes PPARG2, FABP4 and FSP27 (10&#x02009;&#x003bc;M CBD).</p></list-item><list-item id="biof2148-li-0143"><p>&#x02191;PPAR&#x02010; &#x003b3;2 (above 2.5&#x02009;&#x003bc;M CBD).</p></list-item><list-item id="biof2148-li-0144"><p>&#x02191; adipogenesis at concentrations above 5&#x02009;&#x003bc;M in mouse cells and 2.5&#x02009;&#x003bc;M in human cells.</p></list-item><list-item id="biof2148-li-0145"><p>CBD does not increase the expression of the lipolytic genes PNPLA2 and LIPE.</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot id="biof2148-ntgp-0001"><fn id="biof2148-note-0001"><p>Abbreviations: AD, adipogenesis; AD&#x02010;MSC, adipose&#x02010;derived mesenchymal stem cells; alloHCT, allogenic hematopoietic cell transplantation; ALS, amyothrophic lateral sclerosis; AMSC, adipose mesenchymal stem cell; APL, alkaline phosphatase; APSC, apical papilla stem cell; BM&#x02010;MSC, bone marrow mesenchymal stem cells; BRDU, bromodeoxyuridine; CBD, cannabidiol; CM, commercial; DFC, 2&#x02032;,7'dichlorofluoresceindiacetate; DFSC, dental follicle stem cell; DNPH, 2,4&#x02010;dinitrophenylhydrazine; DPSC, dental pulp stem cell; GVHD, graft&#x02010;versus&#x02010;host disease; hGMSC, human gingivial mesenchymal stem cell; hiPSC&#x02010;CM, human induced pluripotent stem cell&#x02010;derived cardiomyocytes; HNP, hybrid nanoparticles; HO&#x02010;1, heme oxigenase&#x02010;1; hPLDSC, human peridontal ligament stem cells; LPS, lipopolysaccharides; MOR, moringin; OTG, osteogenesis; OTP, osteoprotection; OTR, osteoregeneratio; PLGA, poly (lactic&#x02010;co&#x02010;glycolic acid). PPAR&#x02010;&#x003b3;, peroxisome proliferator&#x02010;activated receptor gamma; RS, reticulum stress; RXR&#x02010;&#x003b1;, retinoid X receptor alpha; SSPC, skeletal stem and progenitor cell; TBARS, triobarbituric acid&#x02010;reactive substances; TGF&#x02010;&#x003b2;, transforming growth factor beta.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biof2148-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>CBD and its protective effect on SSC.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Aim</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ref</th><th align="left" valign="bottom" rowspan="1" colspan="1">Stem cell isolation</th><th align="left" valign="bottom" rowspan="1" colspan="1">Methodology</th><th align="left" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">NP</td><td align="left" valign="top" rowspan="1" colspan="1">Ivanov et al.<xref rid="biof2148-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Human embryonic neuronal cells obtained from Gibco/life technologies.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Immunohistochemistry of the markers nestin to evaluate stemness and doublecortin to mark differentiation. Study of proapoptotic markers with ELISA. Study of gene expression and regulation by western blot assay, RT&#x02010;qPCR and evaluation of TNF&#x02010;cell promoter interaction by luciferase assay.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0013"><list-item id="biof2148-li-0146"><p>No negative effect was observed in the use of CBD in neural stem cells (5&#x02013;15&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0147"><p>&#x02193; Sox2 (10&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0148"><p>Protective effect against 5&#x02009;Gy radiation (effective against glioblastoma) at concentrations of 5&#x02013;15&#x02009;&#x003bc;M 0.5&#x02009;h after irradiation.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Hou et al.<xref rid="biof2148-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NE&#x02010;4C neuroectodermal mouse stem cell line. Purchased.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Western blot assay and cell viability assay by MTT.</p>
<p>In vivo:</p>
<p>Male C57Bl/6J mice with depressive behavior. CBD administration at 10&#x02009;mg/kg concentration. RT&#x02010;qPCR, RNA sequencing and transcriptome analysis for gene expression assessment.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:<list list-type="bullet" id="biof2148-list-0014"><list-item id="biof2148-li-0149"><p>CBD reverse the negative effect of corticosterone on NE&#x02010;4C proliferation</p></list-item></list>
</p>
<p>In vivo:<list list-type="bullet" id="biof2148-list-0015"><list-item id="biof2148-li-0150"><p>&#x02193; depressive, &#x02193; serum corticosterone and &#x02193; animal's anxiety.</p></list-item><list-item id="biof2148-li-0151"><p>Reverse abnormal neurogenesis in depressive mice.</p></list-item></list>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Razavi et al.<xref rid="biof2148-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02010;</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vivo:</p>
<p>Adult male albino Wistar rats. CBD dissolved in 10% DMSO and 90% phosphate buffer, injecting 5&#x02009;&#x003bc;L of the solution into the lateral ventricle of the brain (50&#x02009;&#x003bc;g CBD/5&#x02009;&#x003bc;L). After the experiment, the sample was excised and microinjected, and a fluorescence immunohistochemistry assay was performed.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0016"><list-item id="biof2148-li-0152"><p>&#x02191; cell proliferation in abstinence rats</p></list-item><list-item id="biof2148-li-0153"><p>&#x02191; neuroblast by a &#x02191; neurogenesis in abstinence rats.</p></list-item><list-item id="biof2148-li-0154"><p>&#x02193; neuronal degeneration generated by this period.</p></list-item><list-item id="biof2148-li-0155"><p>&#x02193; number of dark neurons by CBD treatment in abstinence rats.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ve&#x0010d;e&#x00159;a et al.<xref rid="biof2148-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">D3 wild type mouse embryonic stem cells and HDAC1 mESC from the mouse blastocysts.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Western Blot to detect proteins related to histone acetylation or deacetylation and cell differentiation.</p>
<p>In vivo:</p>
<p>C57/BL6 mice with schizophrenia. CBD was administered in doses of 10&#x02009;mg/kg or 30&#x02009;mg/kg by injection. Brain cryosectioning and immunocytochemistry with anti&#x02010;Sox2 and anti&#x02010;H3K9.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0017"><list-item id="biof2148-li-0156"><p>&#x02193;NCAM levels in the hippocampus, reversing the abnormal H3K9 deacetylation characteristic in schizophrenia.</p></list-item><list-item id="biof2148-li-0157"><p>&#x02191;the activation of the Sox2 protein, which means that acetylation levels have normalized recovering the stemness of the NSCs</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Rajan et al.<xref rid="biof2148-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">hGMSC cells obtained from human gingival biopsies.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Sequencing of an RNA library and RT&#x02010;qPCR.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0018"><list-item id="biof2148-li-0158"><p>&#x02191; E2F1, NDUFC1, PARD3B, RAPH1, NDUFV3, SDHC, MAP1B, FKBP4; &#x02193; PPP3CC, TARBP2, HTRA2, STRADA, STRADB, TRAK2, CABINI, VDAC1.</p></list-item><list-item id="biof2148-li-0159"><p>&#x02191; MAPKAP1, TRAP1, STK25, STIP1, HSPB1, HERPUD1, NFE2L2; &#x02193; MAPK12, MAPK14, MICAL1, MICAL2, MICAL3.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CP</td><td align="left" valign="top" rowspan="1" colspan="1">Fouda et al.<xref rid="biof2148-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Hamster ovary cells and hiPSC&#x02010;CM. Purchased.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Electrophysiological study of the cell membrane and the activation and inactivation of voltage&#x02010;dependent channels to simulate the action potential.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0019"><list-item id="biof2148-li-0160"><p>CBD protects cells from hyperexcitability and cytotoxicity by acting as a cardioprotective molecule at 5&#x02009;&#x003bc;M doses.</p></list-item><list-item id="biof2148-li-0161"><p>&#x02193;INap, PMA, CPT&#x02010;cAMP and ADP</p></list-item><list-item id="biof2148-li-0162"><p>Right&#x02010;shift the midpoint of activation V<sub>&#x000bd;</sub> and &#x02193; z of activation curve.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Franco&#x02010;vadillo et al.<xref rid="biof2148-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Use of hiPSC&#x02010;CM. Purchased.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Oxidative stress assay and study of cell apoptosis by means of the evaluation of caspases 3/7 activity by luciferases. The viability of cardiomyocytes was determined with a cell extract of human macrophages previously treated with LPS.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0020"><list-item id="biof2148-li-0163"><p>Reversal of the negative electrophysiological effect exerted by LPS on the cell membrane.</p></list-item><list-item id="biof2148-li-0164"><p>CBD reverse ROS levels after LPS or MPLA incubation (5&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0165"><p>= TNF&#x02010;&#x003b1; and IL&#x02010;6 after CBD&#x02010;dose in control cells. &#x02191;TNF&#x02010;&#x003b1; and &#x02193; IL&#x02010;6 after CBD&#x02010;dose in LPS and MPLA&#x02010;stimulated cells (5&#x02009;&#x003bc;M).</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IP</td><td align="left" valign="top" rowspan="1" colspan="1">Chiricosta et al.<xref rid="biof2148-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Human mesenchymal gingival stem cells from human biopsies</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cytotoxic assay by MTT, morphological analysis of cells and Western Blot assays and RNA extraction.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0021"><list-item id="biof2148-li-0166"><p>&#x02193; inflammation through activation of the TGF&#x02010;&#x003b2; pathway and inhibition of the IL&#x02010;1 and JAK/STAT pathways at a concentration of 5&#x02009;&#x003bc;M.</p></list-item><list-item id="biof2148-li-0167"><p>Modification in TNF&#x02010;&#x003b1;, IL&#x02010;1, IL&#x02010;6 and TGF&#x02010;&#x003b2; gene expression</p></list-item><list-item id="biof2148-li-0168"><p>Apoptosis reduction by a caspase eight downregulation.</p></list-item><list-item id="biof2148-li-0169"><p>&#x02193; NF&#x02010;kB</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Yeshurun et al.<xref rid="biof2148-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</td><td colspan="2" align="left" valign="top" rowspan="1">
<p>Clinical trial, phase II:</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;48 patients</p>
<p>CBD dissolved in olive oil at 2.5% with an amount of 150&#x02009;mg per dose, two doses per day. Study of chimerism in bone marrow by XY fluorescence in situ hybridization analysis, DNA amplification and histological study of some samples.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0022"><list-item id="biof2148-li-0170"><p>No toxic effect has been observed in the use of CBD.</p></list-item><list-item id="biof2148-li-0171"><p>Treated patients have not developed acute GVHD during the 30&#x02009;days of treatment. Disease development after CBD discontinuation in eight of the patients.</p></list-item><list-item id="biof2148-li-0172"><p>No significant differences between CBD and historical control patients treated.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ruhl et al.<xref rid="biof2148-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">AMSC obtained from human subcutaneous adipose biopsy samples.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Analysis of metabolic activity using a PrestoBlue assay and cell viability assay by crystal violet. Numerous assays, such as growth factor assessment by ELISA, DNPH protein carbonylation assay, lipid peroxidation assessment by TBARS, Oil Red O staining assay or the chondrogenic tissue assay.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0023"><list-item id="biof2148-li-0173"><p>No IL&#x02010;6 reduction in LPS&#x02010;induced inflammation at low doses (3&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0174"><p>&#x02193; oxidative stress and inflammatory effect of LPS on stem cells.</p></list-item><list-item id="biof2148-li-0175"><p>&#x02191; VEGF production of CBD in a LPS&#x02010;induced culture (&#x02191; vascularization)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Libro et al.<xref rid="biof2148-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">hGMSC obtained from biopsies of healthy patients.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cytofluorimetry for the evaluation of cell markers. RNA library sequencing, RT&#x02010;qPCR and Western Blot to determine gene expression. Finally, immunohistochemistry was performed.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0024"><list-item id="biof2148-li-0176"><p>No morphological differences between normal hGMSC and CBD&#x02010;treated hGMSC.</p></list-item><list-item id="biof2148-li-0177"><p>&#x02193; expression of genes related to NOD&#x02010;like, TNF, Jak&#x02013;STAT and NF&#x02010;kB signaling pathways.</p></list-item><list-item id="biof2148-li-0178"><p>&#x02191; immunitary response inhibitors antigens CD47, CD55, CD276.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ERSP</td><td align="left" valign="top" rowspan="1" colspan="1">Kowalczuk et al.<xref rid="biof2148-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Human adipose&#x02010;derived stem cells HuASC from human biopsies</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Morphology study by confocal microscope. Cell proliferation assay with commercial kit and Ki&#x02010;67 immunostaining. RT&#x02010;qPCR and Western blot. Other studies such as evaluation of oxidative stress, nitric oxide, cell cycle analysis, migration by wound healing assay and B&#x02010;galactosidase activation.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0025"><list-item id="biof2148-li-0179"><p>&#x02191; actine density, rounder nucleus and &#x02191; mitochondrial distribution than stressed and normal ASCs (5&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0180"><p>No proliferative or cytotoxicity effect of CBD in cells at 1, 5 and 10&#x02009;&#x003bc;M. Cytotoxicity effect above 50&#x02009;&#x003bc;M.</p></list-item><list-item id="biof2148-li-0181"><p>&#x02191; proliferation in stressed cells with a CBD pre&#x02010;treatment (5&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0182"><p>&#x02193; cell apoptosis by a &#x02191; Superoxide dismutase 2, Glutathione peroxidase and SIRT1 (5&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0183"><p>&#x02193; TNF&#x02010;&#x003b1;, IL&#x02010;4, IL10, and &#x02191; IL&#x02010;1b (5&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0184"><p>&#x02191; IL&#x02010;6 mRNA but &#x02193; IL&#x02010;6 protein.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OSP</td><td align="left" valign="top" rowspan="1" colspan="1">Bublitz et al.<xref rid="biof2148-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">AD&#x02010;MSC from human subcutaneous adipose tissue.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>RT&#x02010;qPCR, Western Blot and cell metabolism test with WST&#x02010;1</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0026"><list-item id="biof2148-li-0185"><p>&#x02193; apoptosis and &#x02193; ROS by a &#x02191; HO&#x02010;1 protein and mRNA with 3&#x02009;&#x003bc;M CBD dose (max. value after 48&#x02009;h incubation) by a non&#x02010;receptor effect.</p></list-item><list-item id="biof2148-li-0186"><p>&#x02191; metabolic activity after 24&#x02009;h incubation with 1&#x02013;3&#x02009;&#x003bc;M CBD.</p></list-item><list-item id="biof2148-li-0187"><p>slightly &#x02191; autophagy by &#x02191; LC3A/B&#x02010;II.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SE</td><td align="left" valign="top" rowspan="1" colspan="1">Deng et al.<xref rid="biof2148-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NPCs obtained from the forebrain of mouse pups.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Quantification of proliferation by ELISA and WST&#x02010;1.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0027"><list-item id="biof2148-li-0188"><p>&#x02193; viability and proliferation of NPC cells and glioblastoma cells.</p></list-item><list-item id="biof2148-li-0189"><p>CBD&#x02009;+&#x02009;TMZ&#x02009;=&#x02009;no cytotoxicity effect against NPCs (only cancer).</p></list-item><list-item id="biof2148-li-0190"><p>CBD&#x02009;+&#x02009;BCNU&#x02009;=&#x02009;synergistic antiproliferative response (cancer and NPCs).</p></list-item><list-item id="biof2148-li-0191"><p>CBD&#x02009;+&#x02009;BCNU&#x02009;=&#x02009;synergistic, additive and antagonist (cancer and NPCs).</p></list-item><list-item id="biof2148-li-0192"><p>CBD&#x02009;+&#x02009;CDDP&#x02009;=&#x02009;no cytotoxic effect against NPCs (only cancer).</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Libro et al.<xref rid="biof2148-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">hGMSC obtained from biopsies of healthy patients.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Transcription study by deep sequencing of RNA libraries and RT&#x02010;qPCR. Immunocytochemistry.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0028"><list-item id="biof2148-li-0193"><p>&#x02193; of kinase expression (5&#x02009;&#x003bc;M): GSK3&#x003b2;, CDK5, DYRK1A, CAMK2A, MAPK1, MAPK12, MAPK14.</p></list-item><list-item id="biof2148-li-0194"><p>Modulation of the hGMSC transcriptome, &#x02193; expression of genes involved in Alzheimer's pathogenesis.</p></list-item><list-item id="biof2148-li-0195"><p>&#x02193; expression of GSK3b and p&#x02010;GSK303B2, which plays a key role in Alzheimer's disease.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SCR</td><td align="left" valign="top" rowspan="1" colspan="1">Miller et al.<xref rid="biof2148-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">BM&#x02010;MSC and ASC, both obtained from human and porcine biopsies.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cell migration and proliferation assay with MTT in human cells. Wound&#x02010;healing assay in porcine cells.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0029"><list-item id="biof2148-li-0196"><p>&#x02191; migratory capacity in human BM&#x02010;MSCs and ASCs. Higher values of migration with low CBD concentration (300&#x02009;nM) than high ones (3&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0197"><p>&#x02191; proliferation in BM&#x02010;MSCs with a greater effect at low doses (300&#x02009;nM) than at high doses (3&#x02009;&#x003bc;M).</p></list-item><list-item id="biof2148-li-0198"><p>&#x02191; wound closure in porcine cells in the presence of CBD. Higher wound&#x02010;closure with low CBD concentration (300&#x02009;nM).</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DS</td><td align="left" valign="top" rowspan="1" colspan="1">Sun et al.<xref rid="biof2148-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cells obtained from the cerebral cortex of E18 Sprague&#x02013;Dawley rat embryos. The iPSC cell line 6358&#x02013;1 were obtained by reprogramming skin fibroblasts from patients with Dravet syndrome, performed by Stanford University.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Neuronal calcium assay by FLIPR Tetra Cellular Screening System and evaluation of neuronal cell excitability.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0030"><list-item id="biof2148-li-0199"><p>Cytotoxicity effect with high CBD doses after 48&#x02009;h (15&#x02009;&#x003bc;M)</p></list-item><list-item id="biof2148-li-0200"><p>Rat CNC: modulatory effect on the excitability at low concentrations (50&#x02013;500&#x02009;nM).</p></list-item><list-item id="biof2148-li-0201"><p>iPSC: &#x02191; excitability of inhibitory neurons and &#x02193; excitability of excitatory neurons without altering the sodium amplitude of the cells 50&#x02009;nM.</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot id="biof2148-ntgp-0002"><fn id="biof2148-note-0002"><p>Abbreviations: AD&#x02010;MSC, adipose&#x02010;derived mesenchymal stem cells; alloHCT, allogenic hematopoietic cell transplantation; ALS, amyothrophic lateral sclerosis; AMSC, adipose mesenchymal stem cell; APD, AP duration; APL, alkaline phosphatase; APSC, apical papilla stem cell; BM&#x02010;MSC, bone marrow mesenchymal stem cells; BRDU, bromodeoxyuridine; CBD, cannabidiol; CBG, cannabigerol; CM, commercial; CP, cardioprotective; DFC, 2&#x02032;,7'dichlorofluoresceindiacetate; DFSC, dental follicle stem cell; DNPH, 2,4&#x02010;dinitrophenylhydrazine; DPSC, dental pulp stem cell; DS, disease study; ERSP, endoplasmic reticulum stress protection; GVHD, graft&#x02010;versus&#x02010;host disease; hGMSC, human gingivial mesenchymal stem cell; hiPSC&#x02010;CM, human induced pluripotent stem cell&#x02010;derived cardiomyocytes; HO&#x02010;1, heme oxigenase&#x02010;1; hPLDSC, human peridontal ligament stem cells; LPS, lipopolysaccharides; MPLA, monophosphoryl lipid A; NP, neuroprotective; OSP, oxidative stress protection; PLGA, poly (lactic&#x02010;co&#x02010;glycolic acid); PPAR&#x02010;&#x003b3;, peroxisome proliferator&#x02010;activated receptor gamma; rCNC, rat cortical neural cells; RS, reticulum stress; RXR&#x02010;&#x003b1;, receptor X retinoide alfa.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biof2148-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>CBD as an antitumor agent and its effect on CSCs.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Tumor</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ref</th><th align="left" valign="bottom" rowspan="1" colspan="1">In vitro/in vivo</th><th align="left" valign="bottom" rowspan="1" colspan="1">Treatment</th><th align="left" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td rowspan="7" align="left" valign="top" colspan="1">
<p>GBM</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Lah et al.<xref rid="biof2148-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro:<list list-type="bullet" id="biof2148-list-0031"><list-item id="biof2148-li-0202"><p>GBM cell lines: U373 and 9 primary GBM cells from patients (NIB140, NIB142, NIB138, NIB180, NIB185, NIB182, NIB167, NIB258, NIB255)</p></list-item><list-item id="biof2148-li-0203"><p>GBM stem cell (GSC) lines: NCH644 and 7 primary GSC from patients (K26, NIB216, NIB237, NIB225, NIB220, NIB249, NIB253)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Different concentrations (0.32&#x02013;320&#x02009;&#x003bc;M) of CBD alone or combined with CBG at the molar ratio CBD:CBG 3:1 (7.6:2.5&#x02013;245:80&#x02009;&#x003bc;M) with 100&#x02009;&#x003bc;M temozolomide for 48&#x02009;h.</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>IC<sub>50</sub> Values in cells treated with CBD or CBD:CBG (3:1), respectively:<list list-type="bullet" id="biof2148-list-0032"><list-item id="biof2148-li-0204"><p>GBM cell lines: Mean (78.9&#x02009;&#x000b1;&#x02009;7.8; 76&#x02009;&#x000b1;&#x02009;6.6:25&#x02009;&#x000b1;&#x02009;2.1&#x02009;&#x003bc;M)</p></list-item><list-item id="biof2148-li-0205"><p>GSC lines: Mean (50&#x02009;&#x000b1;&#x02009;7.1; 42&#x02009;&#x000b1;&#x02009;3.4:16&#x02009;&#x000b1;&#x02009;1.1&#x02009;&#x003bc;M)</p></list-item></list>
</p>
<p>NCH644 (34; 34:11&#x02009;&#x003bc;M); K26 (73; 54:18&#x02009;&#x003bc;M); NIB216 (24; 30:10&#x02009;&#x003bc;M); NIB237 (50; 27:9&#x02009;&#x003bc;M); NIB225 (50; 28:9&#x02009;&#x003bc;M); NIB220 (84; 38:12&#x02009;&#x003bc;M); NIB249 (52; 46:15&#x02009;&#x003bc;M); NIB253 (35; 30:10&#x02009;&#x003bc;M)</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Volmar et al.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Primary cell cultures of GSC from human GBM biopsies</p>
<p>In vivo:</p>
<p>B6.129S6&#x02010;Rag2<sup>tm1Fwa</sup> N12 (immunodeficient Rag2&#x02010;KO) mice with intracranial orthotopic xenografts of GSC (NCH421K and Line2)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>CBD (10&#x02009;&#x003bc;M) for 6&#x02009;hours</p>
<p>TMZ (100 and 300&#x02009;&#x003bc;M)</p>
<p>Control: 0.01% DMSO</p>
<p>In vivo:</p>
<p>Mice were i.p. injected every other day for 21&#x02009;days with CBD (15&#x02009;mg/kg) or vehicle (5% Tween 80, 5% ethanol in 0.9% saline).</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro CBD treatment:<list list-type="bullet" id="biof2148-list-0033"><list-item id="biof2148-li-0206"><p>Differentially affected the GSC panel, dividing cells into CBD&#x02010;sensitive (Line7, NCH592B, GBM20, NCH684, GBM29, Line6, NCH644, Line2, NCH588J, GBM10, Line11, BT423, BT112) and CBD&#x02010;insensitive (NCH421K, NCH441, Line9, Line8, GBM14, Line10, GBM13, BT172).</p></list-item><list-item id="biof2148-li-0207"><p>&#x02191; cytotoxicity than TMZ in CBD&#x02010;sensitive GSC.</p></list-item></list>
</p>
<p>In vivo CBD treatment:<list list-type="bullet" id="biof2148-list-0034"><list-item id="biof2148-li-0208"><p>&#x02191; survival of mice inoculated with Line2 GSC, but no response in animals bearing NCH421K GSC.</p></list-item></list>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lah et al.<xref rid="biof2148-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>GSCs lines (established lines NCH644, NCH421k, and patient&#x02010;derived K26)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Different concentrations (0.16&#x02013;50&#x02009;&#x003bc;M) of CBG, CBD, and THC alone or combined with TMZ (100&#x02009;&#x003bc;M or 400&#x02009;&#x003bc;M) for 48&#x02009;h</td><td align="left" valign="top" rowspan="1" colspan="1">IC<sub>50</sub> Values<list list-type="bullet" id="biof2148-list-0035"><list-item id="biof2148-li-0209"><p>CBD: NCH644: 15.9&#x02009;&#x003bc;M; NCH421k: 27.9&#x02009;&#x003bc;M; K26: 14.6&#x02009;&#x003bc;M; Mean in GSCs: 19.5&#x02009;&#x000b1;&#x02009;4.2&#x02009;&#x003bc;M</p></list-item><list-item id="biof2148-li-0210"><p>CBG: Mean in GSCs: 59.0&#x02009;&#x000b1;&#x02009;14.7&#x02009;&#x003bc;M</p></list-item><list-item id="biof2148-li-0211"><p>THC: Mean in GSCs: 22.8&#x02009;&#x000b1;&#x02009;3.3&#x02009;&#x003bc;M</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L&#x000f3;pez&#x02010;Valero et al.<xref rid="biof2148-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Glioblastoma patient&#x02010;derived GICs (GH2&#x02010;GICs and 12O12&#x02010;GICs cells)</p>
<p>In vivo:</p>
<p>Orthotopic xenografts 7.5&#x02009;&#x000d7;&#x02009;10<sup>4</sup> 12O12 GICs (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6&#x02013;7) generated by intracranial injection into the right cerebral hemisphere of immunodeficient nude mice</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro (for 5&#x02009;days):<list list-type="bullet" id="biof2148-list-0036"><list-item id="biof2148-li-0212"><p>Vehicle (DMSO)</p></list-item><list-item id="biof2148-li-0213"><p>THC:CBD (1:1 ratio) [2.5&#x02009;&#x003bc;M THC&#x02009;+&#x02009;2.5&#x02009;&#x003bc;M CBD]</p></list-item><list-item id="biof2148-li-0214"><p>THC:CBD (1:5 ratio) [0.83&#x02009;&#x003bc;M THC&#x02009;+&#x02009;4.17&#x02009;&#x003bc;M CBD]</p></list-item><list-item id="biof2148-li-0215"><p>TMZ (100&#x02009;&#x003bc;M in GH2&#x02010;GICs and 20&#x02009;&#x003bc;M in 12O12&#x02010;GICs);</p></list-item></list>
</p>
<p>In vivo (oral admin for 4&#x02009;weeks):<list list-type="bullet" id="biof2148-list-0037"><list-item id="biof2148-li-0216"><p>THC:CBD (1:1 ratio) [THC (5&#x02009;mg/kg)&#x02009;+&#x02009;CBD (5&#x02009;mg/kg)]</p></list-item><list-item id="biof2148-li-0217"><p>THC:CBD (1:5 ratio) [THC (5&#x02009;mg/kg)&#x02009;+&#x02009;CBD (25&#x02009;mg/kg)]</p></list-item><list-item id="biof2148-li-0218"><p>TMZ (5&#x02009;mg/kg, I.P. administration)</p></list-item></list>
</p>
<p>(THC and CBD diluted in sesame oil)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>&#x02193; proliferation:<list list-type="bullet" id="biof2148-list-0038"><list-item id="biof2148-li-0219"><p>GH2&#x02010;GICs: THC:CBD (1:5), or THC:CBD (1:1 or 1:5)&#x02009;+&#x02009;TMZ&#x02009;&#x0003e;&#x02009;THC:CBD (1:1) or TMZ alone</p></list-item><list-item id="biof2148-li-0220"><p>12O12&#x02010;GICs: similar results with the strongest effect with THC:CBD 1:5&#x02009;+&#x02009;TMZ</p></list-item></list>
</p>
<p>&#x02193; neurosphere formation and apoptosis:<list list-type="bullet" id="biof2148-list-0039"><list-item id="biof2148-li-0221"><p>THC:CBD (1:5)&#x02009;&#x0003e;&#x02009;TMZ or THC:CBD (1:1)</p></list-item><list-item id="biof2148-li-0222"><p>THC:CBD (1:5)&#x02009;+&#x02009;TMZ&#x02009;&#x0003e;&#x02009;THC:CBD (1:1)&#x02009;+&#x02009;TMZ</p></list-item></list>
</p>
<p>In vivo:</p>
<p>&#x02193; tumor growth and &#x02191; survival of the animals:<list list-type="bullet" id="biof2148-list-0040"><list-item id="biof2148-li-0223"><p>THC:CBD (1:5)&#x02009;+&#x02009;TMZ&#x02009;&#x0003e;&#x02009;THC:CBD (1:1)&#x02009;+&#x02009;TMZ&#x02009;&#x0003e;&#x02009;TMZ</p></list-item><list-item id="biof2148-li-0224"><p>THC:CBD (1:5): no effect on tumor size but &#x02191; survival of the animals</p></list-item></list>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nabissi et al.<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>GSC lines (#1, #30 and #83) isolated from patients</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Cell viability:<list list-type="bullet" id="biof2148-list-0041"><list-item id="biof2148-li-0225"><p>CBD (from 0.5 to 50&#x02009;&#x003bc;M) for 24&#x02009;h.</p></list-item></list>
</p>
<p>Rest of experiments: 10&#x02009;&#x003bc;M CBD for up to 24&#x02009;hr</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="biof2148-list-0042"><list-item id="biof2148-li-0226"><p>CBD induced activation of autophagy via TRPV2 pathway</p></list-item><list-item id="biof2148-li-0227"><p>&#x02193; viability and proliferation, with IC<sub>50</sub> 24&#x02009;h: 19.4&#x02009;&#x003bc;M (#1); 14.6&#x02009;&#x003bc;M (#30); and 19.3&#x02009;&#x003bc;M (#83)</p></list-item><list-item id="biof2148-li-0228"><p>Cell cycle arrest at G<sub>0</sub>/G<sub>1</sub> phase; &#x02193; neurosphere formation; &#x02193; stem cell markers.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Singer et al.<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Primary GSC lines (3832 and 387)</p>
<p>In vivo:</p>
<p>Two models of intracranial GBM xenografts in female athymic nu/nu mice, established by intracranial injection of a low number (5&#x02009;&#x000d7;&#x02009;10<sup>3</sup>) of luciferase&#x02010;labeled GSC lines 3832 and 387</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Cell viability assay: Range of CBD concentrations for 48&#x02009;h</p>
<p>Rest of experiments: CBD (2&#x02009;&#x003bc;M) alone or with 40&#x02009;&#x003bc;M antioxidant VitE for 48&#x02009;h</p>
<p>In vivo:</p>
<p>CBD (intraperitoneally 15&#x02009;mg/kg, 5&#x02009;days per week)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro CBD treatment:<list list-type="bullet" id="biof2148-list-0043"><list-item id="biof2148-li-0229"><p>&#x02193; viability of 3832 and 387 GSCs (IC<sub>50</sub>: 3.5 and 2.6&#x02009;&#x003bc;M, respectively).</p></list-item><list-item id="biof2148-li-0230"><p>&#x02193; stemness marker and &#x02191; MES markers.</p></list-item></list>
</p>
<p>In vivo CBD treatment:<list list-type="bullet" id="biof2148-list-0044"><list-item id="biof2148-li-0231"><p>&#x02191; survival in tumor&#x02010;bearing mice</p></list-item><list-item id="biof2148-li-0232"><p>&#x02193; p&#x02010;AKT, Ki67 and &#x02191; caspase&#x02010;3 activation in GBM xenograft tissues</p></list-item><list-item id="biof2148-li-0233"><p>&#x02193; tumor size (at day 22), but tumors became resistant to treatment 1&#x02009;week later (day 29)</p></list-item></list>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Soroceanu et al.<xref rid="biof2148-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Neurospheres derived from GBM primary cells from patients</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Neurosphere formation assay: 1&#x02009;&#x003bc;M CBD</td><td align="left" valign="top" rowspan="1" colspan="1">CBD:<list list-type="bullet" id="biof2148-list-0045"><list-item id="biof2148-li-0234"><p>&#x02193; neurosphere formation (reduction of ~60%)</p></list-item><list-item id="biof2148-li-0235"><p>&#x02193; expression levels of Id&#x02010;1 and SOX2 in neurospheres</p></list-item></list>
</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Lung</td><td align="left" valign="top" rowspan="1" colspan="1">Salles et al.<xref rid="biof2148-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vivo:</p>
<p>2 groups (<italic toggle="yes">N</italic>&#x02009;=&#x02009;10/group) of male nude mice with a subcutaneous tumor into the flank (5&#x02009;x&#x02009;10<sup>5</sup> NCI&#x02010;H1437)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Inhalant CBD and placebo (hemp seed oil).</p>
<p>Each animal received 6.4&#x02009;mg of CBD per day (four sprays of 1.6&#x02009;mg of CBD/mouse/day) for 3&#x02009;weeks</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">CBD vs. placebo:<list list-type="bullet" id="biof2148-list-0046"><list-item id="biof2148-li-0236"><p>&#x02193; tumor growth rate</p></list-item><list-item id="biof2148-li-0237"><p>&#x02193; CD44 expression (from 12.1 to 3.2% of total tumor cells) by flow cytometry analysis and by immunohistochemistry</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Misri et al.<xref rid="biof2148-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:<list list-type="bullet" id="biof2148-list-0047"><list-item id="biof2148-li-0238"><p>NSCLC&#x02010;CR cell lines (H460&#x02010;CR and A549&#x02010;CR)</p></list-item><list-item id="biof2148-li-0239"><p>CSC spheres derived from H460&#x02010;CR and A549&#x02010;CR.</p></list-item></list>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>H460&#x02010;CR and A549&#x02010;CR: increasing concentrations of cisplatin and CBD for 48&#x02009;h.</p>
<p>Forming CSC spheres: CBD (15.8&#x02009;&#x003bc;M), or cisplatin (27&#x02009;&#x003bc;M) during sphere formation for 7&#x02013;10&#x02009;days.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">CBD:<list list-type="bullet" id="biof2148-list-0048"><list-item id="biof2148-li-0240"><p>&#x02193; spheres formation in treated NSCLC&#x02010;CR vs. control or cisplatin&#x02010;treated cells.</p></list-item><list-item id="biof2148-li-0241"><p>&#x02193; CD44+ and CD133+ cell population in treated spheres (41.73% in H460&#x02010;CR, and 81.70% in A549&#x02010;CR;) vs. controls (91% in H460, and 95.877% in A549)</p></list-item><list-item id="biof2148-li-0242"><p>&#x02193; protein expression of Snail, Nanog, and Vimentin in both NSCLC&#x02010;CR</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hamad et al.<xref rid="biof2148-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">In vitro:<list list-type="bullet" id="biof2148-list-0049"><list-item id="biof2148-li-0243"><p>NSCLC cell lines (A549 and H1299)</p></list-item><list-item id="biof2148-li-0244"><p>SCLC cell line (H69)</p></list-item><list-item id="biof2148-li-0245"><p>Spheres derived from A549, H1299 and H69</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Viability assay: CBD concentrations (0&#x02013;48&#x02009;&#x003bc;M) for 24&#x02009;h</p>
<p>Sphere formation: Preincubation with 10&#x02009;&#x003bc;M CBD for 24&#x02009;h in the presence or absence of serum</p>
<p>Rest of assays: Spheres were incubated with 10&#x02009;&#x003bc;M CBD for 24&#x02009;h.</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">CBD vs. control:<list list-type="bullet" id="biof2148-list-0050"><list-item id="biof2148-li-0246"><p>&#x02193; viability of NSCLC cell and spheres with different sensibility.</p></list-item><list-item id="biof2148-li-0247"><p>&#x02193; sphere formation.</p></list-item><list-item id="biof2148-li-0248"><p>&#x02193; expression levels of: SOX2, Oct&#x02010;4 and CD133 (in A549 spheres); SOX2 and CD133 (in H1299 spheres) and SOX2, CD44, CD133 and Oct&#x02010;4 (in H69 spheres).</p></list-item><list-item id="biof2148-li-0249"><p>&#x02191; annexin&#x02010;positive cells in A549 spheres (~30%), in H1299 spheres (10%&#x02013;15%) and in H69 spheres.</p></list-item><list-item id="biof2148-li-0250"><p>&#x02191; of caspase 3/7 in A549, H1299 and H69 spheres.</p></list-item><list-item id="biof2148-li-0251"><p>&#x02191; expression of TP53 (3&#x02010;fold), CDKN1A (5&#x02010;fold) and pro&#x02010;apoptotic genes BAK1, BAX, and BAD (~1.8&#x02010;fold) in A549.</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Breast</td><td align="left" valign="top" rowspan="1" colspan="1">Jo et al.<xref rid="biof2148-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>In vitro:</p>
<p>Mammosphere derived from MCF7</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">CBD (2&#x02009;&#x003bc;M) for 2&#x02009;weeks</td><td align="left" valign="top" rowspan="1" colspan="1">CBD:<list list-type="bullet" id="biof2148-list-0051"><list-item id="biof2148-li-0252"><p>&#x02193; formation and growth of mammospheres.</p></list-item><list-item id="biof2148-li-0253"><p>&#x02193; expression levels of stem cell proteins (ALDH1A1, CD133, NANOG, SOX2) in treated mammospheres vs. untreated.</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot id="biof2148-ntgp-0003"><fn id="biof2148-note-0003"><p>Abbreviations: Aml&#x02010;1, acute myeloid leukemia; BCNU, carmustine; CBD, cannabidiol; CR, cisplatin&#x02010;resistant; CSC, cancer stem cell; DMSO, dimethylsulfoxide; ERA, erastin; GBM, glioblastoma multiforme; GICs, glioma initiating cells; GSC, glioblastoma stem cells; IC<sub>50</sub>, half&#x02010;maximal inhibitory concentration; i.p, intraperitoneal; KO, knock&#x02010;out; MES, mesenchymal; NSCLC, non&#x02010;small&#x02010;cell lung cancer; PE, piperazine erastine; PN, proneural; ROS, reactive oxygen species; SAS, sulfasalazine; THC, tetrahidrocannabinol; TMZ, temozolomide.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="biof2148-sec-0008"><label>3</label><title>RESULTS AND DISCUSSION</title><p>The analysis of the 38 selected articles showed that CBD assays in stem cells increased in the past 10&#x02009;years, with 2015, 2021, and 2022 standing out in relation to CSC studies. Assays in SCC also progressively increased during this time (Figure&#x000a0;<xref rid="biof2148-fig-0002" ref-type="fig">2A</xref>). Most of the manuscripts focused on the effect of CBD on SSC (71%) and only a 29% on CSC (Figure&#x000a0;<xref rid="biof2148-fig-0002" ref-type="fig">2B</xref>). These studies used commercial CBD (63%) and CBD from plant extractions (13%). No specific origin was indicated in 24% of the manuscripts (Figure&#x000a0;<xref rid="biof2148-fig-0002" ref-type="fig">2C</xref>).</p><fig position="float" fig-type="FIGURE" id="biof2148-fig-0002"><label>FIGURE 2</label><caption><p>Manuscripts studying the effect of CBD on SSC or CSC over time. Graphical representation of: (A) Number of articles published; (B) Percentage of articles analyzing SSC and CCS; (C) Percentage of articles that use commercial CBD or plant extract.</p></caption><graphic xlink:href="BIOF-51-0-g001" position="anchor" id="jats-graphic-5"/></fig><sec id="biof2148-sec-0009"><label>3.1</label><title>
<styled-content style="fixed-case" toggle="no">CBD</styled-content> enhance stem cell differentiation</title><p>Eleven of the selected articles analyzed the effect of CBD on stem cell differentiation (Table&#x000a0;<xref rid="biof2148-tbl-0001" ref-type="table">1</xref>). Three manuscript used MSCs as a cellular model for the study of osteogenesis,<xref rid="biof2148-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="biof2148-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="biof2148-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> two manuscripts studied osteogenesis in tooth stem cells, specifically apical papilla stem cells (APSCs), dental follicle stem cells (DFSCs) and dental pulp stem cells (DPSCs)<xref rid="biof2148-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="biof2148-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> and only one used skeletal stem and progenitor cells (SSPC).<xref rid="biof2148-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> CBD induced a direct modulation of the transcriptome and gene expression, enhancing the expression of osteogenic genes such as the BMP family<xref rid="biof2148-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
<italic toggle="yes">Runx2</italic>,<xref rid="biof2148-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="biof2148-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="biof2148-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> or <italic toggle="yes">ALP</italic>.<xref rid="biof2148-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="biof2148-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> CBD was also able to modulate some signaling pathways for cell protection, such as the p42/44 MAPK<xref rid="biof2148-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> or p38 MAPK.<xref rid="biof2148-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</p><p>Yu et al.<xref rid="biof2148-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> and Petrescu et al.<xref rid="biof2148-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> studied osteogenesis in tooth stem cells, specifically apical papilla stem cells (APSCs), dental follicle stem cells (DFSCs) and dental pulp stem cells (DPSCs). CBD (2.5 and 12.5&#x02009;&#x003bc;M) increased cell proliferation and protection against inflammation in DPSC and modulated osteogenic gene expression such as <italic toggle="yes">ALP</italic>, osteoporin, osteocalcin, osteonectin, or type 1 collagen. APSC also increased osteogenic gene expression and DFSC shows a mineralization increase. Finally, Ihejirika&#x02010;Lomedico et al.<xref rid="biof2148-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> were the only ones to perform an osteo&#x02010;genic study with SSPC, in which increased expression in the osteogenic genes <italic toggle="yes">Runx2</italic> and <italic toggle="yes">Osterix</italic> was observed. Interestingly, these authors demonstrated that CBD administered via osmotic pump in mice with bone fractures or osteoporosis (induced by ovarectomy or fluoxetine) significantly improved bone regeneration.</p><p>In addition, in vivo studies by Kamali et al.<xref rid="biof2148-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> in mice with bone injury showed an increase in scaffold regenerative capacity in presence of CBD due to an enhancement in the MSC and an osteogenic effect because of an upregulation in the osteogenesis genes osteoporin, osteocalcin, and osteonectin and an increased CB1 and CB2 in DPSC cells. Also, CBD reduced the effect of TNF&#x02010;&#x003b1; on the migration of DPSC at 2, 5&#x02009;&#x003bc;M concentration.</p><p>Nowadays, osteostimulation of endogenous stem cells is the main therapy for bone repair and osteoporosis. There are numerous ways to stimulate the differentiation, recruitment and proliferation of these stem cells, such as electrical stimulation,<xref rid="biof2148-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> physical support,<xref rid="biof2148-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> or drug treatment<xref rid="biof2148-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>, <xref rid="biof2148-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref>, <xref rid="biof2148-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>, <xref rid="biof2148-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>, <xref rid="biof2148-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> which include the endocannabinoids. Most of the articles in this review on osteoregeneration use only the drug except the experiment by Kamali et al. in which this drug enhance the regenerative effect of the scaffold.<xref rid="biof2148-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p><p>Regarding neurogenesis, various authors have demonstrated CBD's ability to enhance stem cell differentiation in the nervous system and reduce inflammation and degeneration processes.<xref rid="biof2148-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="biof2148-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="biof2148-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Cellular exposure to a siRNA and CBD liposome&#x02010;coated nanoparticle increased the cell viability, reduced inflammation, and downregulated the htt gene expression, mitigating the effects of Huntington's disease.<xref rid="biof2148-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> Additionally, CBD promoted SSC survival and neuronal differentiation through PI3K/Akt/mTOR activation, further enhanced by the presence of Moringin.<xref rid="biof2148-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Razavi et al.<xref rid="biof2148-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> conducted an in vivo study using rats previously administered with methamphetamine, showing that CBD treatment increased neurogenesis in the hippocampus and reduced neuronal degeneration. In neuropathy, there are evidences of the positive effect of NSC engraftment as a treatment. However, NSC cells in the adult generate a reduced number of neurons, so they must be accompanied by molecules that enhance neurogenesis.<xref rid="biof2148-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>
</p><p>Finally, Fellous et al.<xref rid="biof2148-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> and Chang et al.<xref rid="biof2148-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> investigated adipogenesis in human and mouse BM&#x02010;MSCs, as well as human AD&#x02010;MSCs. The use of CBD induced PPAR&#x02010;y activation, a protective pro&#x02010;differentiator and an antilipolytic effect by modulating the expression of genes such as <italic toggle="yes">PNPLA2</italic>, <italic toggle="yes">LIPE</italic> or adiponectin. Fellous et al.<xref rid="biof2148-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> evidenced an increased fibroblast colony formation of MSC and upregulation of <italic toggle="yes">Fabp4</italic>, <italic toggle="yes">Glut</italic> and <italic toggle="yes">Scd</italic> genes with a 5&#x02009;&#x003bc;M CBD concentration. On the other hand, Chang et al.<xref rid="biof2148-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> shown an increased lipid accumulation and adipogenesis in mouse and human MSC in a concentration above 5 and 2, 5&#x02009;&#x003bc;M respectively. The interaction of CBD with PPAR&#x02010;&#x003b3; have an important role in the adipogenesis, developing insulin&#x02010;resistance and lipodystrophy in knockout PPAR&#x02010;&#x003b3; MSC cells.<xref rid="biof2148-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>
</p></sec><sec id="biof2148-sec-0010"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">CBD</styled-content> and its protective effect on <styled-content style="fixed-case" toggle="no">SSC</styled-content>
</title><p>Seventeen of the collected manuscripts studied the protective capacity of CBD on SSC (Table&#x000a0;<xref rid="biof2148-tbl-0002" ref-type="table">2</xref>) (Figure&#x000a0;<xref rid="biof2148-fig-0003" ref-type="fig">3</xref>), one of them present in both Tables&#x000a0;<xref rid="biof2148-tbl-0001" ref-type="table">1</xref> and <xref rid="biof2148-tbl-0002" ref-type="table">2</xref>.<xref rid="biof2148-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> CBD was safe against human embryonic neural stem cells and also protected them after a radiation exposure over 5&#x02009;Gy (radiation dose effective against glioblastoma) in an interval of 5 to 15&#x02009;&#x003bc;M with a Sox2 reduction.<xref rid="biof2148-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> Protective effect against radiation has been previously studied with a positive effect, for example, in keratinocytes and melanocytes cultures in CBD concentration of 8 and 4&#x02009;&#x003bc;M respectively, probably by an anti&#x02010;inflammatory and antioxidative effect due to a CB1 and CB2 activation.<xref rid="biof2148-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>, <xref rid="biof2148-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="biof2148-fig-0003"><label>FIGURE 3</label><caption><p>CBD acts as a differentiator inducer in stem cells and has a protective effect on them. Graphical representation of: (A) Percentage of articles studying organogenesis and protective effect; (B) Percentage of studies on adipogenesis, neurogenesis and osteogenesis; (C) Percentage of manuscripts studying neuroprotection, cardioprotection and inflammation among others; (D) Percentage of studies carrying out in vitro, in vivo and clinical trials.</p></caption><graphic xlink:href="BIOF-51-0-g005" position="anchor" id="jats-graphic-7"/></fig><p>The study of Hou et al.<xref rid="biof2148-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> shown an upregulation in FoxO pathway, reducing the impact of corticosterone on an in vitro model of neuroectodermal mouse stem cells.<xref rid="biof2148-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> Also, CBD reduced the corticosterone production and effect on abnormal neurogenesis, anxiety and depressive behavior on CBD&#x02010;treated depressed&#x02010;like mice. Other study shows a reversal of H3K9 deacetylation by a NCAM level reduction and an enhanced acetylation by a Sox2 activation in schizophrenia mice models after the CBD injection.<xref rid="biof2148-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> The NCAM adhesion molecule response can be developed by a CB1 receptor activation, enhancing the neurogenesis and differentiation by a CBD treatment.<xref rid="biof2148-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref>
</p><p>Another disease studied was the Amyotrophic Lateral Sclerosis (ALS), where CBD reduced its development due to a modification of the expression of some genes related to the disease, such excitotoxicity&#x02010;related, oxidative stress&#x02010;related, or mitochondrial dysfunction&#x02010;related genes at a 5&#x02009;&#x003bc;M concentration.<xref rid="biof2148-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Fouda and Franco&#x02010;Vadillo performed the only two manuscripts related to cardioprotection present in this systematic review, using induced human stem cells (hiPSCs) in both of them. Their first study shows a cardioprotective effect of CBD at 5&#x02009;&#x003bc;M concentrations in a pro&#x02010;inflammatory environment and a high glucose&#x02010;induced arrhythmia reversal effect due to a INap, PMA, CTP&#x02010;cAMP, and ADP downregulation, leading a correct cell differentiation under adverse situations. A year later, they studied the protective capacity of the drug against an LPS and MPLA induced inflammation. At 5&#x02009;&#x003bc;M concentration, CBD reversed the abnormal electrophysiology, ADP increment, and caspase&#x02010;3 activity in the LPS and MPLA&#x02010;induced cells. Also, CBD induced a reduction in IL&#x02010;6 and activation in TNF&#x02010;&#x003b1; only in LPS and MPLA&#x02010;induced cells.<xref rid="biof2148-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> CBD can activate RISK pathway and increase the AKT protein production and its phosphorylation into p&#x02010;AKT, producing a beneficial effect in the myocardial reperfusion damage treatment.<xref rid="biof2148-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> Also, CBD can be used as anti&#x02010;inflammatory and antioxidative molecules against a cardiomyopathy due to a reduction in cellular damaging and caspase&#x02010;related apoptosis, a mitochondrial protection and a ionic homeostasis regulation.<xref rid="biof2148-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref>
</p><p>Four of the articles were aimed only in the anti&#x02010;inflammatory effect (Figure&#x000a0;<xref rid="biof2148-fig-0003" ref-type="fig">3</xref>). The research team of Chiricosta et al.<xref rid="biof2148-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> spotted a reduction in the inflammatory response in human mesenchymal gingivial stem cells (5&#x02009;&#x003bc;M CBD), despite of an increased TNF&#x02010;&#x003b1;. This anti&#x02010;inflammatory effect depends on some gene expression modifications that allowed an increased TGF&#x02010;&#x003b2; expression and an inhibition of IL&#x02010;1 and downregulation of the pro&#x02010;inflammatoriy pathway JAK/STAT (and then reducing the IL&#x02010;6 production). Also, a reduction in NF&#x02010;kB production and a caspase 8 downregulation have been shown.<xref rid="biof2148-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> CBD also performed a reduction on the oxidative stress and inflammatory environment effects against adipogenesis without a IL&#x02010;6 reduction and an increased VEGF production in AMSC with low CBD concentration (3&#x02009;&#x003bc;M).<xref rid="biof2148-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> The treatment of hGMSC with CBD reduced the apoptotic activation in the inflammated SSCs by an inhibition and downregulation of some pro&#x02010;apoptotic genes, and upregulation of Bcl&#x02010;2 and PI3K/Akt proteins. In addition, an anti&#x02010;inflammatory effect has been shown due to an inhibition of the NALP3&#x02010;inflammasome complex by a CB1 receptor activation. CBD also reduced the inmune response with a downregulation in genes related to HLA&#x02010;H, GNG1O, NLR, TNF, Jak&#x02013;stat, and NF&#x02010;kB pathways, reduction in macrophage and T&#x02010;cell surface activators and increased anti&#x02010;immune response. An increased CD13, CD29, CD73 and reduced CD44, CD90 and CD199 could lead an increased adipogenesis against a pro&#x02010;inflammatory effect.<xref rid="biof2148-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> One of the most studied CBD properties is the anti&#x02010;inflammatory effect, so its effects in the inflammatory pathways are well known. For example, CBD can reduce the NF&#x02010;&#x003ba;B activity in RAW 264.7 macrophages, probably by a p38 MAP kinase activity.<xref rid="biof2148-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> Also, CBD can be a FKBP5 antagonist, reducing the NF&#x02010;&#x003ba;B activation.<xref rid="biof2148-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> PPAR&#x02010;&#x003b3; receptors also reduce the inflammatory environment reducing the NO, IL&#x02010;1&#x003b2;, IL&#x02010;6, TNF&#x02010;&#x003b1;, iNOS, and COX&#x02010;2 pro&#x02010;inflammatory influence by a NF&#x02010;&#x0039a;b inhibition.<xref rid="biof2148-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> Treatment with CBD can also inhibit IL&#x02010;2 and IFN&#x02010;&#x003b3; expression at 0.5&#x02013;20&#x02009;&#x003bc;M concentration, two important JAK/STAT pathway activators.<xref rid="biof2148-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref>
</p><p>The study carried out by Yeshurun et al.<xref rid="biof2148-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> was the only clinical study on CBD treatment in SSC. This study aimed to determine the capacity of CBD as a treatment for Graft&#x02010;versus&#x02010;Host disease after allogeneic implantation of hematopoietic stem cells. The study involved 48 patients, 28 of them received a donation from their HLA&#x02010;identical sibling, 16 received a donation from an unrelated but 10/10 matched individual and four of them received a donation from an individual with a single antigen mismatch. The doses used in this study were 300&#x02009;mg of CBD each day for 30&#x02009;days, divided into two daily doses of 150&#x02009;mg intakes. The drug was administered orally, dissolved in olive oil at a ratio of 2.5%. The results of this study were positive, experiencing a significant reduction in the incidence of rejection during the 30&#x02009;days of the experiment with no side effects observed, increasing the subsequent development of the disease after the elimination of CBD. Therefore, CBD has great potential in the treatment of this disease and can be added along with standard treatment to obtain better results.</p><p>Some of these studies carried out other pathways of protection of the SSC. One example is the protection against oxidative stress, where CBD (3&#x02009;&#x003bc;M) reduced apoptosis and ROS due to an increased HO&#x02010;1 expression. Also, CBD increased AD&#x02010;MSC metabolic activity with a 1&#x02013;3&#x02009;&#x003bc;M.<xref rid="biof2148-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> The increase of HO&#x02010;1 by CBD is also shown in the endothelial cells HUVEC by an independent TRPV1, CB1 and CB2 pathway, but by a N&#x02010;acetyl&#x02010;L&#x02010;cysteine (NAC) influence.<xref rid="biof2148-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> This study also confirms an increased HUVEC metabolic activity in a 6&#x02009;&#x003bc;M CBD concentration.</p><p>Endoplasmic reticulum stress is also a risk factor against SSC differentiation, and CBD shown a recovery of huASC proliferation and migration as well as a reduction of apoptosis.<xref rid="biof2148-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> Treated SSC with 5&#x02009;&#x003bc;M CBD shown an increased actine density and mitochondrial distribution with a rounder nucleus and an enhanced metabolism. CBD also increased the proliferation only in the stressed cells. CBD&#x02010;treated cells had a similar early apoptosis than untreated cells, but total cell apoptosis decreased by a Superoxide dismutase 2, Glutathione peroxidase and SIRT1 upregulation and P53, BAX and Cas&#x02010;9 downregulation. Also, CBD decreased the inflammatory response by a reduction in IL&#x02010;6 protein production, TNF&#x02010;&#x003b1;, IL&#x02010;4, and IL&#x02010;10 downregulation and IL&#x02010;1b upregulation. Lastly, CBD modified other cell factors like PERK, elF2&#x02010;&#x003b1;, CHOP, IRE, XBP1, etc.<xref rid="biof2148-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> The study of Patel et al.<xref rid="biof2148-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> shown an enhancement in the viability of mouse striatal cells with a CBD pre&#x02010;treatment by an increased GRP78 chaperone and ER&#x02010;resident neurotrophic factor MANF, and a reduction of BIM and caspase&#x02010;12 pro&#x02010;apoptotic molecules.</p><p>Two articles used non&#x02010;stem cell models as principal CBD target, but also studied it effect on SSC to discard any possible side effect. Deng et al.<xref rid="biof2148-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> studied the antitumor effect of CBD in glioblastoma, so they also determined its side effect in NPCs, experiencing a reduction in their viability at the concentration used against glioblastoma. A CBD&#x02010;only treatment reduced viability and proliferation in NPCs, but CBD&#x02009;+&#x02009;TMZ and CBD&#x02009;+&#x02009;CDDP co&#x02010;treatments eliminated this drawback without influencing the antitumoral effect. On the other hand, Libro et al.<xref rid="biof2148-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> used CBD against Alzheimer's disease at 5&#x02009;&#x003bc;M, that leaded a modification in the expression of some genes such a reduction in secretases and kinases, increased ubiquitin&#x02010;conjugating enzymes and heat&#x02010;shock proteins and upregulation of PI3K/Akt protein production. Moreover, CBD reduced the expression of Alzheimer's disease&#x02010;related proteins by a TRPV receptor activation, such GSK3b. There are also evidences about the capacity of CBD to interact with glutamate receptors (NMDA receptors), propionic acid receptors (AMPA receptor) and PPAR&#x02010;&#x003b3;, reducing the amyloid&#x02010;&#x003b2; production.<xref rid="biof2148-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>
</p><p>The study of Miller et al.<xref rid="biof2148-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> shown a proliferation and migration capacity of SSCs in the presence of CBD at concentration of 300&#x02009;nM compared to concentration of 3&#x02009;&#x003bc;M in human and positive wound&#x02010;healing effect in porcine BM&#x02010;MSC and ASC. Finally, Sun and Dolmetsch<xref rid="biof2148-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> studied the use of CBD as a therapy against Dravet syndrome using iPSCs as a model. Concentrations of 50&#x02009;&#x003bc;M modulated the excitability of inhibitory cells and reduced the excitability of excitatory neurons, and also shown a cytotoxicity effect with CBD after 48&#x02009;h above 15&#x02009;&#x003bc;M. Previous studies show the CBD potential as a Dravet syndrome treatment in pediatric clinical trials, enhancing the patient's quality of life and reducing the seizure frequency.<xref rid="biof2148-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref> When the long&#x02010;term efficacy and safety of CBD was examined in children and adults with treatment&#x02010;resistant epilepsy, specifically Lennox&#x02013;Gastaut syndrome and Dravet syndrome, results indicate a median reduction of 50% in major motor seizures and 44% in total seizures after 12&#x02009;weeks of CBD treatment. These effects were maintained for up to 96&#x02009;weeks, with an acceptable safety profile. Common side effects included somnolence and diarrhea, supporting CBD's potential as a long&#x02010;term treatment option for Lennox&#x02013;Gastaut syndrome and Dravet syndrome.<xref rid="biof2148-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref>
</p><p>On the other hand, Peters et al.<xref rid="biof2148-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> explored the impact of cannabidiol (CBD) on the safety and effectiveness of diazepam nasal spray for seizure clusters. Their results indicated that CBD, especially in its FDA&#x02010;approved, highly purified form, did not compromise diazepam's safety or effectiveness. Patients used purified CBD required fewer secondary doses of diazepam compared to those used other or no CBD, with reduced treatment&#x02010;related adverse events, particularly in patients also taking clobazam. This supports safe concurrent use of CBD and diazepam nasal spray for appropriate epilepsy cases.</p></sec><sec id="biof2148-sec-0011"><label>3.3</label><title>The effect of <styled-content style="fixed-case" toggle="no">CBD</styled-content> on cancer stem cells</title><p>Eleven articles evaluated the effect of CBD specifically against CSCs of different tumor types (Figure&#x000a0;<xref rid="biof2148-fig-0004" ref-type="fig">4</xref>). Seven articles studied the effect of CBD on glioblastoma. From them, most studies used GBM stem cells (GSCs) from established lines (e.g., NCH644 or NCH421k) or from primary cultures derived from patient samples. Three of the articles also performed in vivo assays to test the activity of CBD against intracranial GSC&#x02010;derived tumors.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="biof2148-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> In addition, several studies have evaluated the impact of CBD on the formation of neurospheres from GBM patient cells. For instance, Soroceanu et al.<xref rid="biof2148-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> reported a 60% reduction in neurosphere frequency after CBD treatment compared to untreated cells. Additionally, they showed that CBD decreased the expression levels of Id&#x02010;1 and SOX2 in the neurospheres formed.<xref rid="biof2148-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> Id&#x02010;1 is a critical transcriptional regulator of glioblastoma aggressiveness and a marker of cancer stemness, making it a promising new drug target.<xref rid="biof2148-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="biof2148-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="biof2148-fig-0004"><label>FIGURE 4</label><caption><p>CBD presents antitumor activity against different types of aggressive tumors both in vitro and in vivo. Graphic representation of: (A) Types of cancer studied; (B) Percentage of in vitro and in vivo studies; (C) Main results of the effect of CBD on different types of CSC.</p></caption><graphic xlink:href="BIOF-51-0-g002" position="anchor" id="jats-graphic-9"/></fig><p>Volmar et al.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> examined CBD sensitivity in a panel of 21 human GSC lines. They classified the cells as CBD&#x02010;sensitive (Line7, NCH592B, GBM20, NCH684, GBM29, Line6, NCH644, Line2, NCH588J, GBM10, Line11, BT423 and BT112) and CBD&#x02010;insensitive (NCH421K, NCH441, Line9, Line8, GBM14, Line10, GBM13 and BT172). CBD also showed higher cytotoxicity than TMZ in CBD&#x02010;sensitive GSCs.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> These in vitro results were confirmed in vivo using immunodeficient Rag2 KO mice with orthotopic xenografts of GSCs (NCH421K and Line2). CBD administration prolonged the survival of mice inoculated with Line2, classified as a CBD&#x02010;sensitive GSC line, but showed no response in animals bearing NCH421K, a CBD&#x02010;insensitive GSC line. Regarding the mechanism of antitumor action, it was described that CBD effect was mediated by apoptosis or endoplasmic reticulum stress and autophagy in GSCs. In addition, CBD&#x02010;sensitive GSC death was associated with attenuation of canonical NF&#x02010;&#x003ba;B responsiveness, caused by nuclear accumulation and DNA binding of the RelA&#x02010;deficient phospho&#x02010;Ser311 subunit of NF&#x02010;&#x003ba;B. These results were complemented by transcriptomic analysis, which showed the repression of pathologically relevant genes of the RelA pathway, and by the application of a RelA inhibitor (SN50), which prevented the nuclear accumulation of RelA and blocked the cytotoxicity of CBD in Line 2, Line 11 and NCH644. In fact, CBD did not induce nuclear accumulation of RelA in CBD&#x02010;insensitive GSCs. On the other hand, CBD sensitivity was inversely correlated with ROS expression in GSCs both in vitro and in vivo, such that CBD&#x02010;sensitive cells expressed low levels of ROS, whereas CBD&#x02010;insensitive GSCs had high levels of ROS, so that ROS levels could be used as a biomarker for stratifying patients according to responsiveness to CBD treatment.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>
</p><p>The role of ROS was also evaluated by Singer et al.<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> but in this case, they suggested that the cytotoxic effect of CBD in two primary GSC lines, 3832 (IC<sub>50</sub>: 3.5&#x02009;&#x003bc;M) and 387 (IC<sub>50</sub>: 2.6&#x02009;&#x003bc;M), was dependent on ROS action, as it was reversed by the addition of the antioxidant compound vitamin E (vitE). The authors reported that CBD inhibited GSC self&#x02010;renewal by increasing ROS levels, as evidenced by a decrease in sphere&#x02010;forming capacity. This effect was accompanied by activation of the p&#x02010;p38 pathway, downregulation of master regulators of self&#x02010;renewal (p&#x02010;STAT3, SOX2, and Id&#x02010;1), stemness markers (OLIG2), and proneural (PN) markers, and upregulation of mesenchymal (MES) markers (CD44, TNSFR10, CEBPB) in 3832 GSCs.<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> The MES subtype in GBM has been associated with increased aggressiveness, poor patient outcomes, and recurrence of the tumor. In GBM, PMT may be equivalent to epithelial&#x02010;mesenchymal transition, which is associated with other aggressive cancers and is often responsible for resistance to radiation and chemotherapy.<xref rid="biof2148-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref>
</p><p>The study found that CBD treatment resulted in increased levels of the NRF2 targets SLC7A11/xCT and HMOX&#x02010;1, as well as an increase in the nuclear fraction of NRF2, indicating that CBD activates NRF2. Furthermore, inhibiting SLC7A11/xCT genetically or with drugs such as erastin (ERA) and piperazine erastine (PE) enhanced the cytotoxic activity of CBD and increased ROS levels in GSCs. In this study, the effects of CBD were also tested on two intracranial xenograft models of GSC lines 3832 and 387 in immunosuppressed mice. The results showed a significant improvement in survival rates, along with inhibition of p&#x02010;AKT, Ki67, and caspase&#x02010;3 activation in xenograft tissues. Similar to the in vitro results, CBD administration inhibited the expression of Id&#x02010;1 and SOX2, and upregulated CD44 and NRF2. Although the tumor volume was reduced in treated mice until day 22, the tumors became resistant after one week (day 29).<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> CBD has previously been described to upregulate Nrf2, a key regulator of the cellular antioxidant system associated with neuroprotection.<xref rid="biof2148-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref>, <xref rid="biof2148-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref> It has been reported that NRF2 signaling is activated in CSCs and plays a significant role in tumor initiation, metastasis, and therapy resistance.<xref rid="biof2148-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref> In literature, Nrf2 has been shown to play a significant role in ROS&#x02010;mediated chemoresistance,<xref rid="biof2148-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref> as reported by Singer et al.<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> These mechanisms could also explain the resistance by CBD&#x02010;insensitive GSC lines described by Volmar et al.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> which express high levels of ROS and likely have increased expression of cellular antioxidant mechanisms, such as Nrf2, that decrease the ROS production&#x02010;dependent cytotoxic effect of CBD. Furthermore, Volmar et al.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> proposed that co&#x02010;administration of ROS quenching agents could increase the sensitivity of CBD&#x02010;insensitive GSCs. However, Singer et al.<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> contradicted this proposal by demonstrating that the cytotoxic effect of CBD was ROS&#x02010;dependent and was reversed by the addition of the antioxidant compound vitE. They proposed co&#x02010;administration of BBB&#x02010;permeable inhibitors of antioxidant mechanisms like the xCT system, as a strategy to reverse this resistance and enhance the effect of CBD.<xref rid="biof2148-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> Therefore, further studies are needed to determine the role of ROS in CBD action against GSC.</p><p>Autophagy has been described as another mechanism of antitumor activity of CBD. Nabissi et al.<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> described the induction of autophagy in GSC lines by CBD treatment, and detailed the molecular pathways involved in CBD&#x02010;driven autophagy and other molecular mechanisms triggered by its activation. They demonstrated that CBD&#x02010;induced autophagy was mediated by the TRPV2 signaling pathway and described the activation of autophagy genes, the increased expression of autophagy markers including LC3&#x02010;II and Beclin&#x02010;1/PI3K&#x02010;III complexes. They found that autophagy was also regulated by the AKT&#x02010;PI3k/RPS6KBI/PTEN pathway. Furthermore, CBD induces inhibition of viability and proliferation via activation of autophagy in GSC, with IC<sub>50</sub> 24&#x02009;h: 19.4&#x02009;&#x003bc;M (#1); 14.6&#x02009;&#x003bc;M (#30); and 19.3&#x02009;&#x003bc;M (#83); cell cycle arrest at the G<sub>0</sub>/G<sub>1</sub> phase and significant reduction of neurosphere formation. CBD&#x02010;induced autophagy has been associated with the promotion of Aml&#x02010;1a&#x02010;dependent GSCs differentiation, as it significantly decreased stem cell markers (CD133, Oct&#x02010;4, SSEA&#x02010;1 and Nestin) and increased levels of differentiation markers. CBD&#x02010;induced TRPV2&#x02010;dependent autophagy promoted the differentiation of GSCs and reduced their resistance to the cytotoxic effects of BCNU.<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> Studies have shown that TRPV2 expression is lower in high&#x02010;grade gliomas compared to benign tissues. Additionally, increasing TRPV2 expression in low TRPV2&#x02010;expressing glioma cells has been found to inhibit cell survival and induce apoptosis.<xref rid="biof2148-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> CBD is a well&#x02010;known TRPV2 activator 8<xref rid="biof2148-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref>, <xref rid="biof2148-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref>, <xref rid="biof2148-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref> and is able to increase DOXO drug permeation<xref rid="biof2148-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> and, as mentioned above, chemosensitivity to BCNU,<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> in glioma cells. In summary, CBD seems to induce cell death in GSCs through various mechanisms of action, including cell cycle arrest at the G<sub>0</sub>/G<sub>1</sub> phase,<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> apoptosis,<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="biof2148-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> and autophagy.<xref rid="biof2148-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
</p><p>The synergy of CBD and DOXO has been previously evaluated, generating an increased apoptosis and a reduced metastasis. Also, CBD&#x02009;+&#x02009;DOXO can arrest cell cycle in G1 and reduce migration in MDA&#x02010;MB&#x02010;231 triple negative breast cancer cell line in an in vivo and in vitro assay.<xref rid="biof2148-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref> The synergic effect is also observed in glioblastoma, where CBD&#x02010;induced TRPV2 activation reduces the drug resistance of tumor cells, increasing the DOXO intake.<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
</p><p>Some of the studies in GBM evaluated the effects of combining CBD with other cannabinoids, such as CBG, THC, or the chemotherapy drug temozolomide (TMZ). Lah et al.<xref rid="biof2148-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> analyzed the effect of different cannabinoids (CBG, CBD and THC), alone or combined with TMZ, on the viability and GSC lines (NCH644, NCH421k, and patient&#x02010;derived K26). CBD exhibited the highest cytotoxicity in GSCs with IC<sub>50</sub> mean values of 19.5&#x02009;&#x000b1;&#x02009;4.2&#x02009;&#x003bc;M (15.9&#x02009;&#x003bc;M in NCH644; 27.9&#x02009;&#x003bc;M in NCH421k; and 14.6&#x02009;&#x003bc;M in K26) compared to CBG and THC, with IC<sub>50</sub> mean values of 59.0&#x02009;&#x000b1;&#x02009;14.7 and 22.8&#x02009;&#x000b1;&#x02009;3.3&#x02009;&#x003bc;M, respectively. They described that CBD induced apoptosis in GSC line K26 with a 40&#x02013;50% of apoptotic cell population. The combination of CBD:CBG (3:1 ratio) showed an additive response in GSCs (NCH644, NCH421k, K26), but the addition of THC and TMZ did not contributed to any extra cytotoxic effect on these CBD:CBG mixtures. Furthermore, in the GSC line NCH421k, they showed that the combination at 3:1 ratio between CBD and CBG significantly inhibited invasion at nearly 50%, whereas CBD alone showed no statistically significant effect.<xref rid="biof2148-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> In a second publication, the same authors tested the combination of CBD and CBG (3:1 ratio) in eight GSC lines. The GSC lines treated with CBD alone had a mean IC<sub>50</sub> value of 50&#x02009;&#x000b1;&#x02009;7.1&#x02009;&#x003bc;M, whereas the mean IC<sub>50</sub> value was 42&#x02009;&#x000b1;&#x02009;3.4:16&#x02009;&#x000b1;&#x02009;1.1&#x02009;&#x003bc;M when treated with the combination. In NCH644, the IC<sub>50</sub> of CBD alone was 34&#x02009;&#x003bc;M, which was the same value as in the combination of CBD:CBG (34:11&#x02009;&#x003bc;M). The treatments of CBD and CBD:CBG were more effective against GSC than in the GBM lines, had mean IC<sub>50</sub> of 78.9&#x02009;&#x000b1;&#x02009;7.8&#x02009;&#x003bc;M and 76&#x02009;&#x000b1;&#x02009;6.6:25&#x02009;&#x000b1;&#x02009;2.1&#x02009;&#x003bc;M, respectively.<xref rid="biof2148-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref> On the other hand, L&#x000f3;pez&#x02010;Valero et al.<xref rid="biof2148-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> tested the effect of different combinations between THC, CBD and TMZ in cell viability and neurosphere formation of two glioblastoma patient&#x02010;derived glioma initiating cells (GH2&#x02010;GICs and 12O12&#x02010;GICs). Combinations of THC:CBD (1:5 ratio) and THC:CBD (1:1 or 1:5)&#x02009;+&#x02009;TMZ exhibited a higher reduction on the proliferation of GH2&#x02010;GICs than THC:CBD (1:1) or TMZ alone. Similar results were observed in 12O12&#x02010;GICs, with the strongest effect seen with THC:CBD (1:5)&#x02009;+&#x02009;TMZ. Furthermore, the combination of THC:CBD in a 1:5 ratio demonstrated greater inhibition of neurosphere formation compared to THC:CBD in a 1:1 ratio or TMZ alone. However, the most potent inhibition was observed with THC:CBD (1:5)&#x02009;+&#x02009;TMZ, which was also superior to THC:CBD (1:1)&#x02009;+&#x02009;TMZ. Similar results were obtained in vivo in intracranial orthotopic xenografts generated by injecting GICs into immunodeficient nude mice. The combination of THC:CBD (1:5)&#x02009;+&#x02009;TMZ resulted in a significant reduction in tumor growth and increased animal survival rates, surpassing the effects of THC:CBD (1:1)&#x02009;+&#x02009;TMZ or TMZ alone. However, the combination of THC and CBD (1:5) without TMZ did not yield significant results.<xref rid="biof2148-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>
</p><p>Combination studies have shown that a higher amount of CBD in combination with CBG, THC, or TMZ produces a greater effect against GBM stem cells both in vitro and in vivo. The combination of CBD and CBG in a 3:1 ratio,<xref rid="biof2148-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="biof2148-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> as well as THC and CBD in a 1:5 ratio with TMZ,<xref rid="biof2148-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> has been found to be the most effective in inhibiting cell viability and neurosphere formation. In fact, a phase II clinical trial (ARISTOCRAT) with CBD and THC (Sativex) is currently underway for the treatment of unresectable and recurrent glioblastoma. It has been underway since 2022 and pending the publication of results.<xref rid="biof2148-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
</p><p>Regarding lung cancer, three articles were found in which the effect of CBD on lung tumor stem cells was evaluated. Hamad and Olsen<xref rid="biof2148-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> investigated the effects of CBD treatment on sphere formation in two non&#x02010;small cell lung cancer (NSCLC) cell lines (A549 and H1299) and one small cell lung cancer (SCLC) cell line (H69). The results showed that CBD induced a significant reduction in sphere formation in A549, H69 and H1299 cells in serum&#x02010;free medium. CBD also altered CSC marker levels in treated spheres, significantly decreasing SOX2, Oct&#x02010;4 (POU5F1), and CD133 (PROM1) in A549; SOX2 and PROM1 in H1299; and SOX2, CD44, PROM1, and POU5F1 in H69. In addition, CBD increased the number of annexin&#x02010;positive cells, significantly activated caspase 3/7, upregulated the expression of TP53, CDKN1A and pro&#x02010;apoptotic genes BAK1, BAX and BAD, increased ROS levels and caused a significant reduction in mitochondrial membrane potential.<xref rid="biof2148-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> The effect of CBD on sphere formation was also evaluated using two NSCLC cisplatin&#x02010;resistant (CR) cell lines (H460&#x02010;CR and A540&#x02010;CR), by Misri et al.<xref rid="biof2148-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> The results showed a significant reduction in sphere formation compared to untreated or cisplatin&#x02010;treated cells. In addition, the treatment with CDB resulted in a significant decrease in the population of CD44+ and CD133+ cells in CSC spheres. Moreover, there was a significant downregulation of protein expression of Snail, Nanog, and Vimentin in both H460&#x02010;CR and A549&#x02010;CR.<xref rid="biof2148-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> The reduction of CD44 expression in lung cancer cells by the action of CBD treatment was also demonstrated in vivo. Salles et al.<xref rid="biof2148-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> established an in vivo lung cancer model with a subcutaneous tumor from NCI&#x02010;H1437 in nude mice to test CBD treatment. In comparison with placebo&#x02010;treated group, inhalant CBD reduced tumor growth rate and evidenced a decrease in CD44 expression by immunohistochemistry and by flow cytometry analysis with a reduction of CD44+ cells from 12.1% to 3.2% of total tumor cells.<xref rid="biof2148-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> CD44 is a key cancer stem cell biomarker that promotes epithelial&#x02010;mesenchymal transition and is involved in cancer proliferation, invasion, metastasis, and resistance.<xref rid="biof2148-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref> In particular, it has been associated with poor prognosis and metastasis in lung cancer.<xref rid="biof2148-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref>, <xref rid="biof2148-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref> Thus, CD44 constitutes a potential therapeutic target for various cancers.<xref rid="biof2148-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref>
</p><p>Finally, only one article examined CBD's effect on breast cancer CSCs. Jo et al.<xref rid="biof2148-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> found that CBD treatment inhibited MCF7&#x02010;derived mammosphere formation and growth, and significantly reduced stem cell protein expression (ALDH1A1, CD133, NANOG, SOX2) in treated mammospheres.<xref rid="biof2148-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>
</p></sec></sec><sec sec-type="conclusions" id="biof2148-sec-0012"><label>4</label><title>CONCLUSIONS</title><p>This systematic review reveals the regenerative and protective action that CBD presents on the SSCs. CBD can stimulate the differentiation of SSCs into osteogenic, adipogenic and neurogenic cell lines directly by a production or inhibition of key factors involved in cellular genesis or indirectly protecting the SSCs against inflammation, oxidative stress and other harmful agents in cellular genesis, both of them without causing adverse or toxic effects. The positive effect of CBD on osteogenesis is supported by in vivo studies, demonstrating an enhanced bone regeneration with scaffold and without them, and also an improved neural stem cell response. The protective effect of CBD has been also observed in rodent schizophrenia model, disease in which SSC activity is reduced. Nowadays there is not enough clinical trials using CBD as a stem cell stimulator. Only one author studied the effect of CBD as a GVHD treatment in patients with a hematopoietic stem cell implantation, with positive results during the 30&#x02009;days treatment.</p><p>Furthermore, although there are numerous articles that study the antitumor effect of CBD, there are no studies that investigate into its specific activity on CSCs. On the other hand, its effect on CSC has only been studied in three tumor types, making it necessary to extend the studies to other types of aggressive and prevalent tumors. The most studied tumor type is the GBM, in which CBD showed an increased cellular differentiation marker levels while reducing proliferation and cell viability. Moreover, CBD decreases spheroid formation and stem cell marker levels in lung and breast cancers. Among the three tumor types used as study models, only GBM and lung have been studied in vivo, demonstrating a reduction in tumor growth and an increased survival rate and a modified cellular markers expression in CBD&#x02010;treated mice.</p><p>In conclusion, CBD presents a powerful and promising activity in Regenerative Medicine as a differentiator and protector of SCCs and in Oncology as a potential antitumor treatment focused on CSCs. However, this systematic review reveals the existence of few in vivo studies. Therefore, further in vivo studies would be necessary to justify the translational leap of these pharmacological therapies to controlled, randomized clinical trials.</p></sec><sec id="biof2148-sec-0013"><title>AUTHOR CONTRIBUTIONS</title><p>Jose Prados: Conceptualized the manuscript. Cristina Mesas, Javier Moreno and Kevin Doello: Collected the literature, carried out the investigation and wrote the original draft. Mercedes Pe&#x000f1;a used software and supervised manuscript. Jose Prados and Juan M. L&#x000f3;pez&#x02010;Romero, writing&#x02014;review and editing the manuscript. Consolaci&#x000f3;n Melguizo participate in funding acquisition. All authors have read and agreed to the published version of the manuscript.</p></sec><sec id="biof2148-sec-0015"><title>FUNDING INFORMATION</title><p>This research was funded in part by Spanish Ministry of Science, Innovation and Universities, as well as the European Union, through project RTC2019&#x02010;006870&#x02010;1. In addition, this work was supported by funds from research group CTS&#x02010;107 (Andalusian Government).</p></sec><sec sec-type="COI-statement" id="biof2148-sec-0016"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflict of interest.</p></sec></body><back><ack id="biof2148-sec-0014"><title>ACKNOWLEDGMENTS</title><p>M.P. acknowledges the FPU2019 (Ref. FPU19/06170) grant from the Ministerio de Universidades (Spain). Funding for open access charge: Universidad de Granada/CBUA.</p></ack><sec sec-type="data-availability" id="biof2148-sec-0018"><title>DATA AVAILABILITY STATEMENT</title><p>No data was used in the present study.</p></sec><ref-list id="biof2148-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="biof2148-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="biof2148-cit-0001">
<string-name>
<surname>Massi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Solinas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cinquina</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Parolaro</surname>
<given-names>D</given-names>
</string-name>. <article-title>Cannabidiol as potential anticancer drug</article-title>. <source>Br J Clin Pharmacol</source>. <year>2013</year>;<volume>75</volume>(<issue>2</issue>):<fpage>303</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">22506672</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="biof2148-cit-0002">
<string-name>
<surname>Pacher</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>B&#x000e1;tkai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kunos</surname>
<given-names>G</given-names>
</string-name>. <article-title>The endocannabinoid system as an emerging target of pharmacotherapy</article-title>. <source>Pharmacol Rev</source>. <year>2006</year>;<volume>58</volume>(<issue>3</issue>):<fpage>389</fpage>&#x02013;<lpage>462</lpage>.<pub-id pub-id-type="pmid">16968947</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="biof2148-cit-0003">
<string-name>
<surname>Britch</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Babalonis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>
<given-names>SL</given-names>
</string-name>. <article-title>Cannabidiol: pharmacology and therapeutic targets</article-title>. <source>Psychopharmacology (Berl)</source>. <year>2021</year>;<volume>238</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">33221931</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="biof2148-cit-0004">
<string-name>
<surname>Yan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>. <article-title>Antitumor mechanism of cannabidiol hidden behind cancer hallmarks</article-title>. <source>Biochim Biophys Acta Rev Cancer</source>. <year>2023</year>;<volume>1878</volume>(<issue>4</issue>):<elocation-id>188905</elocation-id>.<pub-id pub-id-type="pmid">37164234</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="biof2148-cit-0005">
<string-name>
<surname>Atalay</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jarocka&#x02010;Karpowicz</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Skrzydlewska</surname>
<given-names>E</given-names>
</string-name>. <article-title>Antioxidative and anti&#x02010;inflammatory properties of Cannabidiol</article-title>. <source>Antioxidants (Basel)</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>21</fpage>.<pub-id pub-id-type="pmid">31881765</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="biof2148-cit-0006">
<string-name>
<surname>Valenti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Billi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pancrazi</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Calabria</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Armogida</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Tortora</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Biological effects of cannabidiol on human cancer cells: systematic review of the literature</article-title>. <source>Pharmacol Res</source>. <year>2022</year>;<volume>181</volume>:<elocation-id>106267</elocation-id>.<pub-id pub-id-type="pmid">35643249</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="biof2148-cit-0007">
<string-name>
<surname>Seltzer</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Watters</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>MacKenzie</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Granat</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>D</given-names>
</string-name>. <article-title>Cannabidiol (CBD) as a promising anti&#x02010;cancer drug</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>11</issue>):<fpage>3203</fpage>.<pub-id pub-id-type="pmid">33143283</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="biof2148-cit-0008">
<string-name>
<surname>K&#x000f6;se</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aerts&#x02010;Kaya</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>K&#x000f6;pr&#x000fc;</surname>
<given-names>&#x000c7;Z</given-names>
</string-name>, <string-name>
<surname>Nemutlu</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ku&#x0015f;konmaz</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Karaosmano&#x0011f;lu</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta&#x02010;adrenergic stimulation</article-title>. <source>Exp Hematol</source>. <year>2018</year>;<volume>57</volume>:<fpage>30</fpage>&#x02013;<lpage>41.e1</lpage>.<pub-id pub-id-type="pmid">29030083</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="biof2148-cit-0009">
<string-name>
<surname>Ruhl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Karthaus</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Beier</surname>
<given-names>JP</given-names>
</string-name>. <article-title>The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs</article-title>. <source>Exp Cell Res</source>. <year>2020</year>;<volume>389</volume>(<issue>1</issue>):<elocation-id>111881</elocation-id>.<pub-id pub-id-type="pmid">32006556</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="biof2148-cit-0010">
<string-name>
<surname>Aguado</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Carracedo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Julien</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Velasco</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Milman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mechoulam</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Cannabinoids induce glioma stem&#x02010;like cell differentiation and inhibit Gliomagenesis</article-title>. <source>J Biol Chem</source>. <year>2007</year>;<volume>282</volume>(<issue>9</issue>):<fpage>6854</fpage>&#x02013;<lpage>6862</lpage>.<pub-id pub-id-type="pmid">17202146</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="biof2148-cit-0011">
<string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Hydrogen sulfide maintains dental pulp stem cell function via TRPV1&#x02010;mediated calcium influx</article-title>. <source>Cell Death Dis</source>. <year>2018</year>;<volume>4</volume>:<fpage>1</fpage>.</mixed-citation></ref><ref id="biof2148-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="biof2148-cit-0012">
<string-name>
<surname>Lah</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Majc</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Su&#x00161;nik</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Breznik</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Por&#x0010d;nik</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>The cytotoxic effects of cannabidiol and cannabigerol on glioblastoma stem cells may mostly involve GPR55 and TRPV1 signalling</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>(<issue>23</issue>):<fpage>5918</fpage>.<pub-id pub-id-type="pmid">36497400</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="biof2148-cit-0013">
<string-name>
<surname>Wickramasinghe</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>Sachs</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shewale</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Dhanan&#x02010;Krishnan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Torre</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>PPARdelta activation induces metabolic and contractile maturation of human pluripotent stem cell&#x02010;derived cardiomyocytes</article-title>. <source>Cell Stem Cell</source>. <year>2022</year>;<volume>29</volume>(<issue>4</issue>):<fpage>559</fpage>&#x02013;<lpage>576.e7</lpage>.<pub-id pub-id-type="pmid">35325615</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="biof2148-cit-0014">
<string-name>
<surname>Yang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Targeting cancer stem cell pathways for cancer therapy</article-title>. <source>Signal Transduct Target Ther</source>. <year>2020</year>;<volume>5</volume>(<issue>1</issue>):<fpage>8</fpage>.<pub-id pub-id-type="pmid">32296030</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="biof2148-cit-0015">
<string-name>
<surname>Marques Azzini</surname>
<given-names>GO</given-names>
</string-name>, <string-name>
<surname>Marques Azzini</surname>
<given-names>VO</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Visoni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fusco</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Beker</surname>
<given-names>NS</given-names>
</string-name>, et al. <article-title>Cannabidiol for musculoskeletal regenerative medicine</article-title>. <source>Exp Biol Med (Maywood)</source>. <year>2023</year>;<volume>248</volume>(<issue>5</issue>):<fpage>445</fpage>&#x02013;<lpage>455</lpage>.<pub-id pub-id-type="pmid">37158062</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="biof2148-cit-0016">
<string-name>
<surname>Koltai</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shalev</surname>
<given-names>N</given-names>
</string-name>. <article-title>Anti&#x02010;cancer activity of cannabis sativa phytocannabinoids: molecular mechanisms and potential in the fight against ovarian cancer and stem cells</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>(<issue>17</issue>):<fpage>4299</fpage>.<pub-id pub-id-type="pmid">36077833</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="biof2148-cit-0017">
<string-name>
<surname>Zhong</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies</article-title>. <source>Acta Pharm Sin B</source>. <year>2022</year>;<volume>12</volume>(<issue>4</issue>):<fpage>1761</fpage>&#x02013;<lpage>1780</lpage>.<pub-id pub-id-type="pmid">35847486</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="biof2148-cit-0018">
<string-name>
<surname>McAllister</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Desprez</surname>
<given-names>PY</given-names>
</string-name>. <article-title>The antitumor activity of plant&#x02010;derived non&#x02010;psychoactive cannabinoids</article-title>. <source>J Neuroimmune Pharmacol</source>. <year>2015</year>;<volume>10</volume>(<issue>2</issue>):<fpage>255</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">25916739</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="biof2148-cit-0019">
<string-name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Bo</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Gong</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Inhibitor of differentiation 1 (Id1) in cancer and cancer therapy</article-title>. <source>Int J Med Sci</source>. <year>2020</year>;<volume>17</volume>(<issue>8</issue>):<fpage>995</fpage>&#x02013;<lpage>1005</lpage>.<pub-id pub-id-type="pmid">32410828</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="biof2148-cit-0020">
<string-name>
<surname>Kolios</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Moodley</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Introduction to stem cells and regenerative medicine</article-title>. <source>Respiration</source>. <year>2013</year>;<volume>85</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">23257690</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="biof2148-cit-0021">
<string-name>
<surname>Tian</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Higuchi</surname>
<given-names>A</given-names>
</string-name>. <article-title>Introduction to stem cells</article-title>. <source>Prog Mol Biol Transl Sci</source>. <year>2023</year>;<volume>199</volume>:<fpage>3</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">37678976</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="biof2148-cit-0022">
<string-name>
<surname>Casado&#x02010;D&#x000ed;az</surname>
<given-names>A</given-names>
</string-name>. <article-title>Stem cells in regenerative medicine</article-title>. <source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>18</issue>):<fpage>5460</fpage>.<pub-id pub-id-type="pmid">36143106</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="biof2148-cit-0023">
<string-name>
<surname>Shostak</surname>
<given-names>S</given-names>
</string-name>. <article-title>(Re)defining stem cells</article-title>. <source>Bioessays</source>. <year>2006</year>;<volume>28</volume>(<issue>3</issue>):<fpage>301</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">16479584</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="biof2148-cit-0024">
<string-name>
<surname>Ahmad</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Amiji</surname>
<given-names>MM</given-names>
</string-name>. <article-title>Cancer stem cell&#x02010;targeted therapeutics and delivery strategies</article-title>. <source>Expert Opin Drug Deliv</source>. <year>2017</year>;<volume>14</volume>(<issue>8</issue>):<fpage>997</fpage>&#x02013;<lpage>1008</lpage>.<pub-id pub-id-type="pmid">27866420</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="biof2148-cit-0025">
<string-name>
<surname>Lim</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Mouawad</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gorton</surname>
<given-names>OK</given-names>
</string-name>, <string-name>
<surname>Bubb</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Kwan</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Cancer stem cell characteristics and their potential as therapeutic targets</article-title>. <source>Med Oncol</source>. <year>2021</year>;<volume>38</volume>(<issue>7</issue>):<fpage>76</fpage>.<pub-id pub-id-type="pmid">34050825</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="biof2148-cit-0026">
<string-name>
<surname>Prasetyanti</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Medema</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Intra&#x02010;tumor heterogeneity from a cancer stem cell perspective</article-title>. <source>Mol Cancer</source>. <year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>41</fpage>.<pub-id pub-id-type="pmid">28209166</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="biof2148-cit-0027">
<string-name>
<surname>Ho&#x02010;Shui&#x02010;Ling</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bolander</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rustom</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Luyten</surname>
<given-names>FP</given-names>
</string-name>, <string-name>
<surname>Picart</surname>
<given-names>C</given-names>
</string-name>. <article-title>Bone regeneration strategies: engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives</article-title>. <source>Biomaterials</source>. <year>2018</year>;<volume>180</volume>:<fpage>143</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">30036727</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="biof2148-cit-0028">
<string-name>
<surname>Jin</surname>
<given-names>YZ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Mesenchymal stem cell therapy for bone regeneration</article-title>. <source>Clin Orthop Surg</source>. <year>2018</year>;<volume>10</volume>(<issue>3</issue>):<fpage>271</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">30174801</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="biof2148-cit-0029">
<string-name>
<surname>M&#x000fc;ller</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lemcke</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>David</surname>
<given-names>R</given-names>
</string-name>. <article-title>Stem cell therapy in heart diseases: cell types, mechanisms and improvement strategies</article-title>. <source>Cell Physiol Biochem</source>. <year>2018</year>;<volume>48</volume>(<issue>6</issue>):<fpage>2607</fpage>&#x02013;<lpage>2655</lpage>.<pub-id pub-id-type="pmid">30121644</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="biof2148-cit-0030">
<string-name>
<surname>Sano</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ishigami</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sano</surname>
<given-names>S</given-names>
</string-name>. <article-title>Stem cell therapy in heart disease: limitations and future possibilities</article-title>. <source>Acta Med Okayama</source>. <year>2020</year>;<volume>74</volume>(<issue>3</issue>):<fpage>185</fpage>&#x02013;<lpage>190</lpage>.<pub-id pub-id-type="pmid">32577015</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="biof2148-cit-0031">
<string-name>
<surname>Zakrzewski</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Dobrzy&#x00144;ski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Szymonowicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rybak</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Stem cells: past, present, and future</article-title>. <source>Stem Cell Res Ther</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>68</fpage>.<pub-id pub-id-type="pmid">30808416</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="biof2148-cit-0032">
<string-name>
<surname>Duncan</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Valenzuela</surname>
<given-names>M</given-names>
</string-name>. <article-title>Alzheimer's disease, dementia, and stem cell therapy</article-title>. <source>Stem Cell Res Ther</source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>111</fpage>.<pub-id pub-id-type="pmid">28494803</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="biof2148-cit-0033">
<string-name>
<surname>Grochowski</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Radzikowska</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Maciejewski</surname>
<given-names>R</given-names>
</string-name>. <article-title>Neural stem cell therapy&#x02010;brief review</article-title>. <source>Clin Neurol Neurosurg</source>. <year>2018</year>;<volume>173</volume>:<fpage>8</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">30053745</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="biof2148-cit-0034">
<string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zou</surname>
<given-names>C</given-names>
</string-name>. <article-title>Current progress in stem cell therapy for type 1 diabetes mellitus</article-title>. <source>Stem Cell Res Ther</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>275</fpage>.<pub-id pub-id-type="pmid">32641151</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="biof2148-cit-0035">
<string-name>
<surname>Huang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>Q</given-names>
</string-name>. <article-title>Stem cell therapy for spinal cord injury</article-title>. <source>Cell Transplant</source>. <year>2021</year>;<volume>30</volume>:<elocation-id>963689721989266</elocation-id>.<pub-id pub-id-type="pmid">33559479</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="biof2148-cit-0036">
<string-name>
<surname>Uprety</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Remon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Adjei</surname>
<given-names>AA</given-names>
</string-name>. <article-title>All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC</article-title>. <source>J Thorac Oncol</source>. <year>2021</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1429</fpage>&#x02013;<lpage>1433</lpage>.<pub-id pub-id-type="pmid">34425994</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="biof2148-cit-0037">
<string-name>
<surname>Sekulic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Migden</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Oro</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Dirix</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Hainsworth</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Efficacy and safety of vismodegib in advanced basal&#x02010;cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>(<issue>23</issue>):<fpage>2171</fpage>&#x02013;<lpage>2179</lpage>.<pub-id pub-id-type="pmid">22670903</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="biof2148-cit-0038">
<string-name>
<surname>Tham</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yilmaz</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Alaverdashvili</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>MEM</given-names>
</string-name>, <string-name>
<surname>Denovan&#x02010;Wright</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Laprairie</surname>
<given-names>RB</given-names>
</string-name>. <article-title>Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol&#x02010;dimethylheptyl at the type 1 and type 2 cannabinoid receptors</article-title>. <source>Br J Pharmacol</source>. <year>2018</year>;<volume>176</volume>(<issue>10</issue>):<fpage>1455</fpage>.<pub-id pub-id-type="pmid">29981240</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="biof2148-cit-0039">
<string-name>
<surname>Muka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Glisic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Milic</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Verhoog</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bohlius</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bramer</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>A 24&#x02010;step guide on how to design, conduct, and successfully publish a systematic review and meta&#x02010;analysis in medical research</article-title>. <source>Eur J Epidemiol</source>. <year>2020</year>;<volume>35</volume>(<issue>1</issue>):<fpage>49</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">31720912</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="biof2148-cit-0040">
<string-name>
<surname>Cohen</surname>
<given-names>J</given-names>
</string-name>. <article-title>Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit</article-title>. <source>Psychol Bull</source>. <year>1968</year>;<volume>70</volume>(<issue>4</issue>):<fpage>213</fpage>&#x02013;<lpage>220</lpage>.<pub-id pub-id-type="pmid">19673146</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="biof2148-cit-0041">
<string-name>
<surname>Kamali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Oryan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hosseini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ghanian</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Alizadeh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Baghaban Eslaminejad</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Cannabidiol&#x02010;loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical&#x02010;sized bone defects</article-title>. <source>Mater Sci Eng C</source>. <year>2019</year>;<volume>101</volume>:<fpage>64</fpage>&#x02013;<lpage>75</lpage>.</mixed-citation></ref><ref id="biof2148-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="biof2148-cit-0042">
<string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xuan</surname>
<given-names>Y w</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y x</given-names>
</string-name>, et al. <article-title>Cannabidiol promotes osteogenic differentiation of bone marrow mesenchymal stem cells in the inflammatory microenvironment via the CB2&#x02010;dependent p38 MAPK signaling pathway</article-title>. <source>Int J Stem Cells</source>. <year>2022</year>;<volume>15</volume>(<issue>4</issue>):<fpage>405</fpage>&#x02013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">35220282</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="biof2148-cit-0043">
<string-name>
<surname>Petrescu</surname>
<given-names>NB</given-names>
</string-name>, <string-name>
<surname>Jurj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sori&#x0021b;&#x00103;u</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Lucaciu</surname>
<given-names>OP</given-names>
</string-name>, <string-name>
<surname>Dirzu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Raduly</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Cannabidiol and vitamin D3 impact on osteogenic differentiation of human dental mesenchymal stem cells</article-title>. <source>Medicina (Kaunas)</source>. <year>2020</year>;<volume>56</volume>(<issue>11</issue>):<fpage>607</fpage>.<pub-id pub-id-type="pmid">33198232</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="biof2148-cit-0044">
<string-name>
<surname>Schmuhl</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ramer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Salamon</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hinz</surname>
<given-names>B</given-names>
</string-name>. <article-title>Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK</article-title>. <source>Biochem Pharmacol</source>. <year>2014</year>;<volume>87</volume>(<issue>3</issue>):<fpage>489</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">24304686</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="biof2148-cit-0045">
<string-name>
<surname>Yu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Cannabidiol rescues TNF&#x02010;&#x003b1;&#x02010;inhibited proliferation, migration, and osteogenic/odontogenic differentiation of dental pulp stem cells</article-title>. <source>Biomolecules</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>118</fpage>.<pub-id pub-id-type="pmid">36671503</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="biof2148-cit-0046">
<string-name>
<surname>Ihejirika&#x02010;Lomedico</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Buchalter</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Kirby</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Mehta</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dankert</surname>
<given-names>JF</given-names>
</string-name>, et al. <article-title>Non&#x02010;psychoactive cannabidiol prevents osteoporosis in an animal model and increases cell viability, proliferation, and osteogenic gene expression in human skeletal stem and progenitor cells</article-title>. <source>Calcif Tissue Int</source>. <year>2023</year>;<volume>112</volume>(<issue>6</issue>):<fpage>716</fpage>&#x02013;<lpage>726</lpage>.<pub-id pub-id-type="pmid">37093268</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="biof2148-cit-0047">
<string-name>
<surname>Fihurka</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Sava</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Sanchez&#x02010;Ramos</surname>
<given-names>J</given-names>
</string-name>. <article-title>Dual&#x02010;function hybrid nanoparticles with gene silencing and anti&#x02010;inflammatory effects</article-title>. <source>Nanomedicine (Lond)</source>. <year>2022</year>;<volume>17</volume>(<issue>9</issue>):<fpage>577</fpage>&#x02013;<lpage>590</lpage>.<pub-id pub-id-type="pmid">35373577</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="biof2148-cit-0048">
<string-name>
<surname>Razavi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Keyhanfar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Haghparast</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shabani</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mehdizadeh</surname>
<given-names>M</given-names>
</string-name>. <article-title>Cannabidiol promotes neurogenesis in the dentate gyrus during an abstinence period in rats following chronic exposure to methamphetamine</article-title>. <source>Metab Brain Dis</source>. <year>2021</year>;<volume>36</volume>(<issue>6</issue>):<fpage>1381</fpage>&#x02013;<lpage>1390</lpage>.<pub-id pub-id-type="pmid">34143376</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="biof2148-cit-0049">
<string-name>
<surname>Lanza Cariccio</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Scionti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Raffa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Iori</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pollastro</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Diomede</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Treatment of periodontal ligament stem cells with MOR and CBD promotes cell survival and neuronal differentiation via the PI3K/Akt/mTOR pathway</article-title>. <source>Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>(<issue>8</issue>):<fpage>2341</fpage>.<pub-id pub-id-type="pmid">30096889</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="biof2148-cit-0050">
<string-name>
<surname>Fellous</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>De Maio</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kalkan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Carannante</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Boccella</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Petrosino</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Phytocannabinoids promote viability and functional adipogenesis of bone marrow&#x02010;derived mesenchymal stem cells through different molecular targets</article-title>. <source>Biochem Pharmacol</source>. <year>2020</year>;<volume>175</volume>:<elocation-id>113859</elocation-id>.<pub-id pub-id-type="pmid">32061773</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="biof2148-cit-0051">
<string-name>
<surname>Chang</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Thangavelu</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Joloya</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Blumberg</surname>
<given-names>B</given-names>
</string-name>. <article-title>Cannabidiol promotes adipogenesis of human and mouse mesenchymal stem cells via PPAR&#x003b3; by inducing lipogenesis but not lipolysis</article-title>. <source>Biochem Pharmacol</source>. <year>2022</year>;<volume>197</volume>:<elocation-id>114910</elocation-id>.<pub-id pub-id-type="pmid">35026188</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="biof2148-cit-0052">
<string-name>
<surname>Ivanov</surname>
<given-names>VN</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hei</surname>
<given-names>TK</given-names>
</string-name>. <article-title>Regulation of human glioblastoma cell death by combined treatment of cannabidiol, &#x003b3;&#x02010;radiation and small molecule inhibitors of cell signaling pathways</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>43</issue>):<fpage>74068</fpage>&#x02013;<lpage>74095</lpage>.<pub-id pub-id-type="pmid">29088769</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="biof2148-cit-0053">
<string-name>
<surname>Hou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Cannabidiol prevents depressive&#x02010;like behaviors through the modulation of neural stem cell differentiation</article-title>. <source>Front Med</source>. <year>2022</year>;<volume>16</volume>(<issue>2</issue>):<fpage>227</fpage>&#x02013;<lpage>239</lpage>.<pub-id pub-id-type="pmid">35212887</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="biof2148-cit-0054">
<string-name>
<surname>Ve&#x0010d;e&#x00159;a</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>B&#x000e1;rtov&#x000e1;</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Krej&#x0010d;&#x000ed;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Legartov&#x000e1;</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kom&#x0016f;rkov&#x000e1;</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rud&#x000e1;&#x02010;Ku&#x0010d;erov&#x000e1;</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia&#x02010;like animals</article-title>. <source>J Cell Physiol</source>. <year>2018</year>;<volume>233</volume>(<issue>1</issue>):<fpage>530</fpage>&#x02013;<lpage>548</lpage>.<pub-id pub-id-type="pmid">28300292</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="biof2148-cit-0055">
<string-name>
<surname>Rajan</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Scionti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Diomede</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Grassi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pollastro</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Piattelli</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Gingival stromal cells as an in vitro model: Cannabidiol modulates genes linked with amyotrophic lateral sclerosis</article-title>. <source>J Cell Biochem</source>. <year>2017</year>;<volume>118</volume>(<issue>4</issue>):<fpage>819</fpage>&#x02013;<lpage>828</lpage>.<pub-id pub-id-type="pmid">27714895</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="biof2148-cit-0056">
<string-name>
<surname>Fouda</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Ruben</surname>
<given-names>PC</given-names>
</string-name>. <article-title>Protein kinases mediate anti&#x02010;inflammatory effects of cannabidiol and estradiol against high glucose in cardiac sodium channels</article-title>. <source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>668657</elocation-id>.<pub-id pub-id-type="pmid">33995099</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="biof2148-cit-0057">
<string-name>
<surname>Franco&#x02010;Vadillo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Toledo&#x02010;Blass</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rivera&#x02010;Herrera</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Guevara&#x02010;Balcazar</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Orihuela&#x02010;Rodriguez</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Morales&#x02010;Carmona</surname>
<given-names>JA</given-names>
</string-name>, et al. <article-title>Cannabidiol&#x02010;mediated RISK PI3K/AKT and MAPK/ERK pathways decreasing reperfusion myocardial damage</article-title>. <source>Pharmacology Res &#x00026; Perspec</source>. <year>2021</year>;<volume>9</volume>(<issue>4</issue>):<elocation-id>e00784</elocation-id>.</mixed-citation></ref><ref id="biof2148-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="biof2148-cit-0058">
<string-name>
<surname>Yeshurun</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shpilberg</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Herscovici</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shargian</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dreyer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Peck</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Cannabidiol for the prevention of graft&#x02010;versus&#x02010;host&#x02010;disease after allogeneic hematopoietic cell transplantation: results of a phase II study</article-title>. <source>Biol Blood Marrow Transplant</source>. <year>2015</year>;<volume>21</volume>(<issue>10</issue>):<fpage>1770</fpage>&#x02013;<lpage>1775</lpage>.<pub-id pub-id-type="pmid">26033282</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="biof2148-cit-0059">
<string-name>
<surname>Ruhl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Beier</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Cannabidiol restores differentiation capacity of LPS exposed adipose tissue mesenchymal stromal cells</article-title>. <source>Exp Cell Res</source>. <year>2018</year>;<volume>370</volume>(<issue>2</issue>):<fpage>653</fpage>&#x02013;<lpage>662</lpage>.<pub-id pub-id-type="pmid">30036540</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="biof2148-cit-0060">
<string-name>
<surname>Libro</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Scionti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Diomede</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Marchisio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Grassi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pollastro</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Cannabidiol modulates the immunophenotype and inhibits the activation of the inflammasome in human gingival mesenchymal stem cells</article-title>. <source>Front Physiol</source>. <year>2016</year>;<volume>7</volume>:<fpage>559</fpage>.<pub-id pub-id-type="pmid">27932991</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="biof2148-cit-0061">
<string-name>
<surname>Kowalczuk</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Marycz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kornicka&#x02010;Garbowska</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kornicka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bujalska&#x02010;Zadro&#x0017c;ny</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Groborz</surname>
<given-names>S</given-names>
</string-name>. <article-title>Cannabidiol (CBD) protects adipose&#x02010;derived mesenchymal stem cells (ASCs) against endoplasmic reticulum stress development and its complications</article-title>. <source>Int J Environ Res Public Health</source>. <year>2022</year>;<volume>19</volume>(<issue>17</issue>):<fpage>10864</fpage>.<pub-id pub-id-type="pmid">36078578</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="biof2148-cit-0062">
<string-name>
<surname>Bublitz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>B&#x000f6;ckmann</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hinz</surname>
<given-names>B</given-names>
</string-name>. <article-title>Cannabinoid&#x02010;induced autophagy and heme oxygenase&#x02010;1 determine the fate of adipose tissue&#x02010;derived mesenchymal stem cells under stressful conditions</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>10</issue>):<fpage>2298</fpage>.<pub-id pub-id-type="pmid">33076330</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="biof2148-cit-0063">
<string-name>
<surname>Deng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ozawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stella</surname>
<given-names>N</given-names>
</string-name>. <article-title>Quantitative analyses of synergistic responses between cannabidiol and DNA&#x02010;damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2017</year>;<volume>360</volume>(<issue>1</issue>):<fpage>215</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">27821713</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="biof2148-cit-0064">
<string-name>
<surname>Libro</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Diomede</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Scionti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Piattelli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Grassi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pollastro</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Cannabidiol modulates the expression of alzheimer's disease&#x02010;related genes in mesenchymal stem cells</article-title>. <source>Int J Mol Sci</source>. <year>2016</year>;<volume>18</volume>(<issue>1</issue>):<fpage>26</fpage>.<pub-id pub-id-type="pmid">28025562</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="biof2148-cit-0065">
<string-name>
<surname>Miller</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>De Leo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Badach</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Williamson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bonawitz</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Role of marijuana components on the regenerative ability of stem cells</article-title>. <source>Cell Biochem Funct</source>. <year>2021</year>;<volume>39</volume>(<issue>3</issue>):<fpage>432</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="pmid">33349985</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="biof2148-cit-0066">
<string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dolmetsch</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Investigating the therapeutic mechanism of cannabidiol in a human induced pluripotent stem cell (ipsc)&#x02010;based model of Dravet syndrome</article-title>. <source>Cold Spring Harb Symp Quant Biol</source>. <year>2018</year>;<volume>83</volume>:<fpage>185</fpage>&#x02013;<lpage>191</lpage>.<pub-id pub-id-type="pmid">31186344</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="biof2148-cit-0067">
<string-name>
<surname>Volmar</surname>
<given-names>MNM</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alenezi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Richter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haug</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hassan</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Cannabidiol converts NF&#x02010;&#x003ba;B into a tumor suppressor in glioblastoma with defined antioxidative properties</article-title>. <source>Neuro Oncol</source>. <year>2021</year>;<volume>23</volume>(<issue>11</issue>):<fpage>1898</fpage>&#x02013;<lpage>1910</lpage>.<pub-id pub-id-type="pmid">33864076</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="biof2148-cit-0068">
<string-name>
<surname>Lah</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pena Almidon</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Marinelli</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>&#x0017d;var Ba&#x00161;kovi&#x0010d;</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Majc</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>(<issue>2</issue>):<fpage>340</fpage>.<pub-id pub-id-type="pmid">33562819</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="biof2148-cit-0069">
<string-name>
<surname>L&#x000f3;pez&#x02010;Valero</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Saiz&#x02010;Ladera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ndez&#x02010;Tiedra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Garc&#x000ed;a&#x02010;Taboada</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rodr&#x000ed;guez&#x02010;Forn&#x000e9;s</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide</article-title>. <source>Biochem Pharmacol</source>. <year>2018</year>;<volume>157</volume>:<fpage>266</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">30195736</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="biof2148-cit-0070">
<string-name>
<surname>Nabissi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morelli</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Amantini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liberati</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Santoni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ricci&#x02010;Vitiani</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Cannabidiol stimulates Aml&#x02010;1a&#x02010;dependent glial differentiation and inhibits glioma stem&#x02010;like cells proliferation by inducing autophagy in a TRPV2&#x02010;dependent manner</article-title>. <source>Int J Cancer</source>. <year>2015</year>;<volume>137</volume>(<issue>8</issue>):<fpage>1855</fpage>&#x02013;<lpage>1869</lpage>.<pub-id pub-id-type="pmid">25903924</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="biof2148-cit-0071">
<string-name>
<surname>Singer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Judkins</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Salomonis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Matlaf</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Soteropoulos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McAllister</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Reactive oxygen species&#x02010;mediated therapeutic response and resistance in glioblastoma</article-title>. <source>Cell Death Dis</source>. <year>2015</year>;<volume>6</volume>(<issue>1</issue>):<elocation-id>e1601</elocation-id>.<pub-id pub-id-type="pmid">25590811</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="biof2148-cit-0072">
<string-name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Murase</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Limbad</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Singer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Allison</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Adrados</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Id&#x02010;1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target</article-title>. <source>Cancer Res</source>. <year>2013</year>;<volume>73</volume>(<issue>5</issue>):<fpage>1559</fpage>&#x02013;<lpage>1569</lpage>.<pub-id pub-id-type="pmid">23243024</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="biof2148-cit-0073">
<string-name>
<surname>Salles</surname>
<given-names>&#x000c9;L</given-names>
</string-name>, <string-name>
<surname>Naeini</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Khodadadi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bhandari</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rezaee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Threlkeld</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Inhalant cannabidiol impedes tumor growth through decreased tumor stemness and impaired angiogenic switch in NCI&#x02010;H1437&#x02010;induced human lung cancer model</article-title>. <source>Hum Cell</source>. <year>2023</year>;<volume>36</volume>(<issue>3</issue>):<fpage>1204</fpage>&#x02013;<lpage>1210</lpage>.<pub-id pub-id-type="pmid">36737540</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="biof2148-cit-0074">
<string-name>
<surname>Misri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaul</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mishra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Charan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Verma</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Barr</surname>
<given-names>MP</given-names>
</string-name>, et al. <article-title>Cannabidiol inhibits tumorigenesis in cisplatin&#x02010;resistant non&#x02010;small cell lung cancer via TRPV2</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1181</fpage>.<pub-id pub-id-type="pmid">35267489</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="biof2148-cit-0075">
<string-name>
<surname>Hamad</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>BB</given-names>
</string-name>. <article-title>Cannabidiol induces cell death in human lung cancer cells and cancer stem cells</article-title>. <source>Pharmaceuticals (Basel)</source>. <year>2021</year>;<volume>14</volume>(<issue>11</issue>):<fpage>1169</fpage>.<pub-id pub-id-type="pmid">34832951</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="biof2148-cit-0076">
<string-name>
<surname>Jo</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>WY</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Yun</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Cannabidiol suppresses angiogenesis and stemness of breast cancer cells by downregulation of hypoxia&#x02010;inducible factors&#x02010;1&#x003b1;</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>(<issue>22</issue>):<fpage>5667</fpage>.<pub-id pub-id-type="pmid">34830821</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="biof2148-cit-0077">
<string-name>
<surname>Khaw</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Xue</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cassidy</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Cartmell</surname>
<given-names>SH</given-names>
</string-name>. <article-title>Electrical stimulation of titanium to promote stem cell orientation, elongation and osteogenesis</article-title>. <source>Acta Biomater</source>. <year>2022</year>;<volume>139</volume>:<fpage>204</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">34390847</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="biof2148-cit-0078">
<string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>A 3D biomimetic optoelectronic scaffold repairs cranial defects</article-title>. <source>Sci Adv</source>. <year>2023</year>;<volume>9</volume>(<issue>7</issue>):<elocation-id>e7750</elocation-id>.</mixed-citation></ref><ref id="biof2148-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="biof2148-cit-0079">
<string-name>
<surname>Kitao</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukui</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shoji</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takeda</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A novel oral anti&#x02010;osteoporosis drug with osteogenesis&#x02010;promoting effects via osteoblast differentiation</article-title>. <source>Yakugaku Zasshi</source>. <year>2019</year>;<volume>139</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">30606923</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="biof2148-cit-0080">
<string-name>
<surname>Xue</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>. <article-title>7,8&#x02010;Dihydroxyflavone modulates bone formation and resorption and ameliorates ovariectomy&#x02010;induced osteoporosis</article-title>. <source>Elife</source>. <year>2021</year>;<volume>10</volume>:<elocation-id>e64872</elocation-id>.<pub-id pub-id-type="pmid">34227467</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="biof2148-cit-0081">
<string-name>
<surname>Ramesh</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jagadeesan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sekaran</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dhanasekaran</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vimalraj</surname>
<given-names>S</given-names>
</string-name>. <article-title>Flavonoids: classification, function, and molecular mechanisms involved in bone remodelling</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>779638</elocation-id>.<pub-id pub-id-type="pmid">34887836</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="biof2148-cit-0082">
<string-name>
<surname>Yan</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>L</given-names>
</string-name>. <article-title>The cannabinoid receptor I (CB1) enhanced the osteogenic differentiation of BMSCs by rescue impaired mitochondrial metabolism function under inflammatory condition</article-title>. <source>Stem Cell Res Ther</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>22</fpage>.<pub-id pub-id-type="pmid">35063024</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="biof2148-cit-0083">
<string-name>
<surname>Yan</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>CB1 enhanced the osteo/dentinogenic differentiation ability of periodontal ligament stem cells via p38 MAPK and JNK in an inflammatory environment</article-title>. <source>Cell Prolif</source>. <year>2019</year>;<volume>52</volume>(<issue>6</issue>):<elocation-id>e12691</elocation-id>.<pub-id pub-id-type="pmid">31599069</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="biof2148-cit-0084">
<string-name>
<surname>De Gioia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Biella</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Citterio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Abati</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nizzardo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Neural stem cell transplantation for neurodegenerative diseases</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>9</issue>):<fpage>3103</fpage>.<pub-id pub-id-type="pmid">32354178</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="biof2148-cit-0085">
<string-name>
<surname>Khosropoor</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alavi</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Etemad</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Roohbakhsh</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cannabidiol goes nuclear: the role of PPAR&#x003b3;</article-title>. <source>Phytomedicine</source>. <year>2023</year>;<volume>114</volume>:<elocation-id>154771</elocation-id>.<pub-id pub-id-type="pmid">36965374</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="biof2148-cit-0086">
<string-name>
<surname>Gohad</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McCoy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wambier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kovacevic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Situm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stanimirovic</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Novel cannabidiol sunscreen protects keratinocytes and melanocytes against ultraviolet B radiation</article-title>. <source>J Cosmet Dermatol</source>. <year>2021</year>;<volume>20</volume>(<issue>4</issue>):<fpage>1350</fpage>&#x02013;<lpage>1352</lpage>.</mixed-citation></ref><ref id="biof2148-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="biof2148-cit-0087">
<string-name>
<surname>Vacek</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vostalova</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Papouskova</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Skarupova</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kabelac</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Antioxidant function of phytocannabinoids: molecular basis of their stability and cytoprotective properties under UV&#x02010;irradiation</article-title>. <source>Free Radic Biol Med</source>. <year>2021</year>;<volume>164</volume>:<fpage>258</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">33453360</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="biof2148-cit-0088">
<string-name>
<surname>Galve&#x02010;Roperh</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Chiurchi&#x000f9;</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>D&#x000ed;az&#x02010;Alonso</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Guzm&#x000e1;n</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</string-name>. <article-title>Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation</article-title>. <source>Prog Lipid Res</source>. <year>2013</year>;<volume>52</volume>(<issue>4</issue>):<fpage>633</fpage>&#x02013;<lpage>650</lpage>.<pub-id pub-id-type="pmid">24076098</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="biof2148-cit-0089">
<string-name>
<surname>Garza&#x02010;Cervantes</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ramos&#x02010;Gonz&#x000e1;lez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lozano</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jerjes&#x02010;S&#x000e1;nchez</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Garc&#x000ed;a&#x02010;Rivas</surname>
<given-names>G</given-names>
</string-name>. <article-title>Therapeutic applications of cannabinoids in cardiomyopathy and heart failure</article-title>. <source>Oxid Med Cell Longev</source>. <year>2020</year>;<volume>2020</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="biof2148-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="biof2148-cit-0090">
<string-name>
<surname>Chiricosta</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Silvestro</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pizzicannella</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Diomede</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bramanti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Trubiani</surname>
<given-names>O</given-names>
</string-name>, et al. <article-title>Transcriptomic analysis of stem cells treated with moringin or cannabidiol: analogies and differences in inflammation pathways</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>(<issue>23</issue>):<fpage>6039</fpage>.<pub-id pub-id-type="pmid">31801206</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="biof2148-cit-0091">
<string-name>
<surname>Silva</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>
<given-names>GT</given-names>
</string-name>, <string-name>
<surname>Wanderlei</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Cecilio</surname>
<given-names>NT</given-names>
</string-name>, <string-name>
<surname>Maganin</surname>
<given-names>AGM</given-names>
</string-name>, <string-name>
<surname>Franchin</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>DMH&#x02010;CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF&#x02010;kB activity dependent on A2A receptor</article-title>. <source>Toxicol Appl Pharmacol</source>. <year>2019</year>;<volume>368</volume>:<fpage>63</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">30796934</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="biof2148-cit-0092">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>. <article-title>Cannabidiol alleviates neuroinflammation and attenuates neuropathic pain via targeting FKBP5</article-title>. <source>Brain Behav Immun</source>. <year>2023</year>;<volume>111</volume>:<fpage>365</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">37196785</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="biof2148-cit-0093">
<string-name>
<surname>Peyravian</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Deo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Daunert</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jimenez</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Cannabidiol as a novel therapeutic for immune modulation</article-title>. <source>ITT</source>. <year>2020</year>;<volume>9</volume>:<fpage>131</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">32903924</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="biof2148-cit-0094">
<string-name>
<surname>B&#x000f6;ckmann</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hinz</surname>
<given-names>B</given-names>
</string-name>. <article-title>Cannabidiol promotes endothelial cell survival by heme oxygenase&#x02010;1&#x02010;mediated autophagy</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>7</issue>):<fpage>1703</fpage>.<pub-id pub-id-type="pmid">32708634</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="biof2148-cit-0095">
<string-name>
<surname>Patel</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Abu&#x02010;Hijleh</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rigg</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mishra</surname>
<given-names>R</given-names>
</string-name>. <article-title>Cannabidiol protects striatal neurons by attenuating endoplasmic reticulum stress. Cannabis and cannabinoid</article-title>. <source>Research</source>. <year>2022</year>;<volume>8</volume>(<issue>2</issue>):<fpage>299</fpage>&#x02013;<lpage>308</lpage>.</mixed-citation></ref><ref id="biof2148-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="biof2148-cit-0096">
<string-name>
<surname>de Brito Siqueira</surname>
<given-names>ALG</given-names>
</string-name>, <string-name>
<surname>Cremasco</surname>
<given-names>PVV</given-names>
</string-name>, <string-name>
<surname>Bah&#x000fa;</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Pioli da Silva</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Melo de Andrade</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Gonz&#x000e1;lez</surname>
<given-names>PGA</given-names>
</string-name>, et al. <article-title>Phytocannabinoids: pharmacological effects, biomedical applications, and worldwide prospection</article-title>. <source>J Tradit Complement Med</source>. <year>2023</year>;<volume>13</volume>(<issue>6</issue>):<fpage>575</fpage>&#x02013;<lpage>587</lpage>.<pub-id pub-id-type="pmid">38020546</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="biof2148-cit-0097">
<string-name>
<surname>Aderinto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Olatunji</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kokori</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ajayi</surname>
<given-names>YI</given-names>
</string-name>, <string-name>
<surname>Akinmoju</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ayedun</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet syndrome: a narrative review of clinical trials</article-title>. <source>Eur J Med Res</source>. <year>2024</year>;<volume>29</volume>(<issue>1</issue>):<fpage>182</fpage>.<pub-id pub-id-type="pmid">38500226</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="biof2148-cit-0098">
<string-name>
<surname>Laux</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Bebin</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Checketts</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Flamini</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>
<given-names>ED</given-names>
</string-name>, et al. <article-title>Long&#x02010;term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox&#x02010;Gastaut syndrome or Dravet syndrome: expanded access program results</article-title>. <source>Epilepsy Res</source>. <year>2019</year>;<volume>154</volume>:<fpage>13</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">31022635</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="biof2148-cit-0099">
<string-name>
<surname>Peters</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Puri</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Misra</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Rabinowicz</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Carrazana</surname>
<given-names>E</given-names>
</string-name>. <article-title>Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: post hoc analysis of a phase 3 safety study</article-title>. <source>Epilepsy Behav</source>. <year>2023</year>;<volume>144</volume>:<elocation-id>109248</elocation-id>.<pub-id pub-id-type="pmid">37210793</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="biof2148-cit-0100">
<string-name>
<surname>Sachdeva</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Smiljanic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaskun</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ghannad&#x02010;Zadeh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Celebre</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>ID1 is critical for tumorigenesis and regulates chemoresistance in glioblastoma</article-title>. <source>Cancer Res</source>. <year>2019</year>;<volume>79</volume>(<issue>16</issue>):<fpage>4057</fpage>&#x02013;<lpage>4071</lpage>.<pub-id pub-id-type="pmid">31292163</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="biof2148-cit-0101">
<string-name>
<surname>Fedele</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cerchia</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pegoraro</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sgarra</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Manfioletti</surname>
<given-names>G</given-names>
</string-name>. <article-title>Proneural&#x02010;mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>(<issue>11</issue>):<fpage>2746</fpage>.<pub-id pub-id-type="pmid">31167470</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="biof2148-cit-0102">
<string-name>
<surname>Kuret</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kreft</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Romih</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Verani&#x0010d;</surname>
<given-names>P</given-names>
</string-name>. <article-title>Cannabidiol as a promising therapeutic option in IC/BPS: in vitro evaluation of its protective effects against inflammation and oxidative stress</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>5</issue>):<fpage>5055</fpage>.<pub-id pub-id-type="pmid">36902479</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="biof2148-cit-0103">
<string-name>
<surname>Sivandzade</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Prasad</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bhalerao</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cucullo</surname>
<given-names>L</given-names>
</string-name>. <article-title>NRF2 and NF&#x02010;&#x0049b;B interplay in cerebrovascular and neurodegenerative disorders: molecular mechanisms and possible therapeutic approaches</article-title>. <source>Redox Biol</source>. <year>2019</year>;<volume>21</volume>:<elocation-id>101059</elocation-id>.</mixed-citation></ref><ref id="biof2148-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="biof2148-cit-0104">
<string-name>
<surname>Hallis</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Kwak</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Emerging role of NRF2 signaling in cancer stem cell phenotype</article-title>. <source>Mol Cells</source>. <year>2023</year>;<volume>46</volume>(<issue>3</issue>):<fpage>153</fpage>&#x02013;<lpage>164</lpage>.<pub-id pub-id-type="pmid">36994474</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="biof2148-cit-0105">
<string-name>
<surname>Xue</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Qiu</surname>
<given-names>J</given-names>
</string-name>. <article-title>Emerging role of NRF2 in ROS&#x02010;mediated tumor chemoresistance</article-title>. <source>Biomed Pharmacother</source>. <year>2020</year>;<volume>131</volume>:<elocation-id>110676</elocation-id>.<pub-id pub-id-type="pmid">32858502</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="biof2148-cit-0106">
<string-name>
<surname>Liberati</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Morelli</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Amantini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Farfariello</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Santoni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Conti</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Loss of TRPV2 homeostatic control of cell proliferation drives tumor progression</article-title>. <source>Cells</source>. <year>2014</year>;<volume>3</volume>(<issue>1</issue>):<fpage>112</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">24709905</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="biof2148-cit-0107">
<string-name>
<surname>Qin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Neeper</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hutchinson</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Lubin</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Flores</surname>
<given-names>CM</given-names>
</string-name>. <article-title>TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons</article-title>. <source>J Neurosci</source>. <year>2008</year>;<volume>28</volume>(<issue>24</issue>):<fpage>6231</fpage>&#x02013;<lpage>6238</lpage>.<pub-id pub-id-type="pmid">18550765</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="biof2148-cit-0108">
<string-name>
<surname>Pumroy</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Samanta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yudin</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Molecular mechanism of TRPV2 channel modulation by cannabidiol</article-title>. <source>Elife</source>. <year>2019</year>;<volume>8</volume>:<elocation-id>e48792</elocation-id>.<pub-id pub-id-type="pmid">31566564</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="biof2148-cit-0109">
<string-name>
<surname>Gochman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>XF</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Swartz</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Jara&#x02010;Oseguera</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cannabidiol sensitizes TRPV2 channels to activation by 2&#x02010;APB</article-title>. <source>Elife</source>. <year>2023</year>;<volume>12</volume>:<elocation-id>e86166</elocation-id>.<pub-id pub-id-type="pmid">37199723</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="biof2148-cit-0110">
<string-name>
<surname>Patel</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kommineni</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Surapaneni</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Kalvala</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yaun</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Gebeyehu</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Cannabidiol loaded extracellular vesicles sensitize triple&#x02010;negative breast cancer to doxorubicin in both in&#x02010;vitro and in vivo models</article-title>. <source>Int J Pharm</source>. <year>2021</year>;<volume>607</volume>:<elocation-id>120943</elocation-id>.<pub-id pub-id-type="pmid">34324983</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="biof2148-cit-0111">
<string-name>
<surname>Bhaskaran</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Savage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Collinson</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mant</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Boele</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi&#x02010;centre, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>BMC Cancer</source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>83</fpage>.<pub-id pub-id-type="pmid">38225549</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="biof2148-cit-0112">
<string-name>
<surname>Thapa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>GD</given-names>
</string-name>. <article-title>The importance of CD44 as a stem cell biomarker and therapeutic target in cancer</article-title>. <source>Stem Cells Int</source>. <year>2016</year>;<volume>2016</volume>:<elocation-id>2087204</elocation-id>.<pub-id pub-id-type="pmid">27200096</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="biof2148-cit-0113">
<string-name>
<surname>Hu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>. <article-title>CD44 promotes cell proliferation in non&#x02010;small cell lung cancer</article-title>. <source>Oncol Lett</source>. <year>2018</year>;<volume>15</volume>(<issue>4</issue>):<fpage>5627</fpage>&#x02013;<lpage>5633</lpage>.<pub-id pub-id-type="pmid">29552200</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="biof2148-cit-0114">
<string-name>
<surname>Wang</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Vadhan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Chao</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>KH</given-names>
</string-name>, et al. <article-title>CD44 promotes lung cancer cell metastasis through ERK&#x02013;ZEB1 signaling</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>(<issue>16</issue>):<fpage>4057</fpage>.<pub-id pub-id-type="pmid">34439211</pub-id>
</mixed-citation></ref><ref id="biof2148-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="biof2148-cit-0115">
<string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Niu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>A</given-names>
</string-name>. <article-title>CD44 as a tumor biomarker and therapeutic target</article-title>. <source>Exp Hematol Oncol</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>36</fpage>.<pub-id pub-id-type="pmid">33303029</pub-id>
</mixed-citation></ref></ref-list></back></article>